1,048 results on '"Sandra E. Black"'
Search Results
202. Biomarkers of agitation in moderate‐to‐severe Alzheimer's disease patients enrolled in an RCT with nabilone
- Author
-
Sandra E. Black, Nathan Herrmann, Damien Gallagher, Krista L. Lanctôt, Myuri Ruthirakuhan, Nicolaas Paul L.G. Verhoeff, and Ana Cristina Andreazza
- Subjects
Moderate to severe ,medicine.medical_specialty ,Epidemiology ,business.industry ,Health Policy ,Disease ,law.invention ,Nabilone ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
203. Association of ventricular size on executive function and attention is modified by Apolipoprotein E and moderated by pulse pressure in Alzheimer's disease
- Author
-
Shraddha Sapkota, G. Peggy McFall, Roger A. Dixon, Sandra E. Black, and Mario Masellis
- Subjects
Apolipoprotein E ,medicine.medical_specialty ,Ventricular size ,Epidemiology ,business.industry ,Health Policy ,Disease ,Pulse pressure ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Neuroimaging ,Internal medicine ,medicine ,Cardiology ,Neurology (clinical) ,Geriatrics and Gerontology ,Association (psychology) ,business ,Function (biology) - Published
- 2020
- Full Text
- View/download PDF
204. How much can the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS‐Cog) tell us? Insights from a latent state‐trait auto‐regressive (LST‐AR) model
- Author
-
Walter Swardfager, Michael Eid, Saffire H. Krance, Hugo Cogo-Moreira, Krista L. Lanctôt, Sandra E. Black, Bradley J. MacIntosh, Jennifer S. Rabin, and Nathan Herrmann
- Subjects
Scale (ratio) ,Epidemiology ,Health Policy ,Neuropsychology ,Cognition ,medicine.disease ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Adas cog ,Autoregressive model ,Trait ,medicine ,Dementia ,Neurology (clinical) ,Disease assessment ,Geriatrics and Gerontology ,Psychology ,Clinical psychology - Published
- 2020
- Full Text
- View/download PDF
205. Neuropsychiatric symptom burden across neurodegenerative disorders and its association with function
- Author
-
Sandra E. Black, Kelly M Sunderland, Paula M. McLaughlin, Mario Masellis, Richard H. Swartz, Bruce G. Pollock, Corinne E. Fischer, Elizabeth Finger, Carmela Tartaglia, John Turnbull, Donna Kwan, Tarek K. Rajji, Daniel Kapustin, David F. Tang‐Wai, Wei Wang, Stephen C. Strother, Gustavo Saposnik, Lorne Zinman, Heather Hink, Brian Tan, Anthony E. Lang, Sanjeev Kumar, Morris Freedman, and Shadi Zarei
- Subjects
medicine.medical_specialty ,Epidemiology ,business.industry ,Health Policy ,media_common.quotation_subject ,Association (object-oriented programming) ,Symptom burden ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Medicine ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Function (engineering) ,Psychiatry ,media_common - Published
- 2020
- Full Text
- View/download PDF
206. Fractional anisotropy in white matter hyperintensities is linked to associative memory performance
- Author
-
Demetrios J. Sahlas, Stephen R. Arnott, Seyyed M. H. Haddad, Manuel Montero-Odasso, Brian Tan, Dar Dowlatshahi, Stephen C. Strother, Donna Kwan, Leanne K. Casaubon, Miracle Ozzoude, Nuwan D. Nanayakkara, Richard H. Swartz, Jennifer Mandzia, Ayman Hassan, Sean P. Symons, Sandra E. Black, Gustavo Saposnik, Melissa F. Holmes, Robert Bartha, and Christopher J.M. Scott
- Subjects
Physics ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Nuclear magnetic resonance ,Developmental Neuroscience ,Epidemiology ,Health Policy ,Fractional anisotropy ,Neurology (clinical) ,Geriatrics and Gerontology ,Content-addressable memory ,Hyperintensity - Published
- 2020
- Full Text
- View/download PDF
207. Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans
- Author
-
Claudia Chevrefils, Sylvain Beaulieu, Tharick A. Pascoal, Hossam El Shahawy, Ziad S Nasreddine, David S. Knopman, Sam Osseiran, Peter J. Kertes, Frédéric Lesage, Sandra E. Black, John J Chen, Sylvia Villeneuve, Jean-Philippe Sylvestre, Céline Chayer, Marc-André Rhéaume, Jean Daniel Arbour, Val J. Lowe, Pedro Rosa-Neto, Alain Robillard, Serge Gauthier, and Jean-Paul Soucy
- Subjects
Pathology ,medicine.medical_specialty ,Epidemiology ,business.industry ,Health Policy ,Amyloid pet ,Retinal ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Developmental Neuroscience ,chemistry ,medicine ,Neurology (clinical) ,Geriatrics and Gerontology ,business - Published
- 2020
- Full Text
- View/download PDF
208. Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: A stratified longitudinal observational study
- Author
-
Bradley J. MacIntosh, Natasha Z. Anita, Krista L. Lanctôt, Nathan Herrmann, Pearl Yang, Jodi D. Edwards, Baiju R. Shah, Michael Ouk, Moira K. Kapral, Yuen Yan Wong, Che-Yuan Wu, Sandra E. Black, Jennifer S. Rabin, and Walter Swardfager
- Subjects
Pediatrics ,medicine.medical_specialty ,Oral hypoglycemic ,Epidemiology ,business.industry ,Health Policy ,Type 2 diabetes ,medicine.disease ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Medicine ,Observational study ,Neurology (clinical) ,Geriatrics and Gerontology ,business - Published
- 2020
- Full Text
- View/download PDF
209. Abnormal brain structure mediates the association between ApoE4 and slow gait among patients with pathological cognitive impairment: Results from the Ontario Neurodegenerative Research Initiative
- Author
-
Derek Beaton, Paula M. McLaughlin, Robert A. Hegele, Frederico Faria-Pieruccini, Kelly M Sunderland, Malcolm A. Binns, Ryota Sakurai, Michael Borrie, Morris Freedman, Carmela Tartaglia, Ben Cornish, Anthony E. Lang, Bill McIlroy, Sean P. Symons, Angela Roberts, Brian Tan, Korbin Blue, Robert Bartha, Donna Kwan, Sandra E. Black, Richard H. Swartz, Stephen C. Strother, Allison A Dilliott, Stephen H. Pasternak, Seyyed M. H. Haddad, Joel Ramirez, Manuel Montero-Odasso, Douglas P. Munoz, and Mario Masellis
- Subjects
medicine.medical_specialty ,Epidemiology ,Behavioral neurology ,business.industry ,Health Policy ,Neuropsychiatry ,medicine.disease ,Research initiative ,Gait ,Psychiatry and Mental health ,Cellular and Molecular Neuroscience ,Physical medicine and rehabilitation ,Developmental Neuroscience ,medicine ,Dementia ,Neurology (clinical) ,Geriatrics and Gerontology ,Cognitive impairment ,Association (psychology) ,business ,Pathological - Published
- 2020
- Full Text
- View/download PDF
210. Where Does Wealth Come From?
- Author
-
Kjell G. Salvanes, Sandra E. Black, Paul J. Devereux, and Fanny Landaud
- Subjects
Inequality ,Capital income ,media_common.quotation_subject ,Labor income ,Economics ,National wealth ,Demographic economics ,Wealth distribution ,media_common - Abstract
Much attention has been given to rising wealth inequality in recent decades. However, understanding inequality requires an understanding of how wealth relates to the potential wealth an individual could accumulate and where this wealth comes from. Using administrative data from Norway, we create measures of potential wealth that abstract from differential consumption and spending behavior. We then examine how these measures relate to observed net wealth of individuals at a point in time and the role played by different sources of wealth in the distribution of potential wealth. We find that net wealth is a reasonable proxy for potential wealth, particularly in the tails of the distribution. Importantly, people in different parts of the potential wealth (or actual net wealth) distribution get their wealth from very different sources. Labor income is the most important determinant of wealth, except among the top 1%, where capital income and capital gains on financial assets become important. Inheritances and gifts are not an important determinant of wealth, even at the top of the wealth distribution. Finally, although inheritances are not important, parental wealth does influence child’s wealth; children of wealthy parents accumulate wealth from very different sources than children of less wealthy parents.
- Published
- 2020
- Full Text
- View/download PDF
211. Government aid and child refugees’ economic success later in life: Evidence from post-WWII GDR refugees
- Author
-
Sandra E. Black, Hannah Liepmann, Camille Remigereau, and Alexandra Spitz-Oener
- Subjects
Organizational Behavior and Human Resource Management ,Economics and Econometrics - Published
- 2022
- Full Text
- View/download PDF
212. Reply to: Rethink the classical view of cerebrospinal fluid production
- Author
-
Kenneth Smith, Joanna M. Wardlaw, Sandra E. Black, Serge Charpak, Berislav V. Zlokovic, and Helene Benveniste
- Subjects
Cellular and Molecular Neuroscience ,medicine.medical_specialty ,Cerebrospinal fluid ,business.industry ,medicine ,MEDLINE ,Production (economics) ,Neurology (clinical) ,Intensive care medicine ,business - Published
- 2021
- Full Text
- View/download PDF
213. Ventricular expansion, white matter hyperintensities, and global cognition in Alzheimer’s disease and normal aging
- Author
-
Mario Masellis, Fuqiang Gao, Sandra E. Black, Joel Ramirez, Zotovic L, Sabrina Adamo, and Melissa F. Holmes
- Subjects
medicine.medical_specialty ,business.industry ,Cognition ,medicine.disease ,Hyperintensity ,Atrophy ,Cerebrospinal fluid ,Internal medicine ,medicine ,Cardiology ,Dementia ,Biomarker (medicine) ,Alzheimer's disease ,Cognitive decline ,business - Abstract
BackgroundThe progression of Alzheimer’s Disease (AD) may be tracked by measuring the growth of the ventricular cerebrospinal fluid (vCSF) over time. AD is commonly comorbid with markers of cerebral small vessel disease (SVD), viewed on MRI as white matter hyperintensities (WMH). Larger WMH volumes are correlated with poorer cognitive test scores. Additionally, periventricular WMHs have a proposed relationship to the vCSF.PurposeThis study will examine ventricular expansion and its associations between periventricular/deep WMH and cognition in AD and normal aging.MethodsBaseline and 1-year follow-up data were collected from AD (n=117) and cognitively normal control (NCs; n=49) participants taking part in the Sunnybrook Dementia Study. MRI (1.5T) and scores from both the Mini-Mental State Examination (MMSE) and the Dementia Rating Scale (DRS) were assessed at each time point. Volumetric data was generated using a semi-automated pipeline and each individual’s vCSF and WMHs were transformed to an intermediate space to determine volumetric growth. Regressions were used to determine relationships between vCSF growth measures, SVD burden, and cognition, accounting for demographics and individual interscan intervals.ResultsThe AD group displayed 14.6% annual ventricular growth as opposed to NC who had only 11.8% annual growth. AD showed significant growth in vCSF (p < 0.001), a trend toward greater pWMH growth (p = 0.06) and no difference in dWMH growth volumes compared to NC. vCSF growth was positively associated with pWMH (β = 0.32, p < 0.001) but not dWMH growth in AD while in NC it was associated with both pWMH (β = 0.48, p < 0.001) and dWMH growth (β = 0.35, p = 0.02). In AD, vCSF growth was associated with the both the MMSE (β = -0.30, p < 0.001) and the DRS (β = -0.31, p < 0.001) in separate models.ConclusionsThe findings from this study suggest that in just under 1.5 years, the significantly rapid ventricular expansion observed in AD may be closely related to periventricular small vessel disease. As vCSF growth rates are an important biomarker of AD neurodegeneration that corresponds with cognitive decline, future research should further explore atrophy associated with periventricular vasculopathy.Trial RegistrationClinicalTrials.gov, NCT01800214. Registered on 27 February 2013.
- Published
- 2020
- Full Text
- View/download PDF
214. Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis
- Author
-
Ramita Dewan, Ruth Chia, Jinhui Ding, Richard A. Hickman, Thor D. Stein, Yevgeniya Abramzon, Sarah Ahmed, Marya S. Sabir, Makayla K. Portley, Arianna Tucci, Kristina Ibáñez, F.N.U. Shankaracharya, Pamela Keagle, Giacomina Rossi, Paola Caroppo, Fabrizio Tagliavini, Maria L. Waldo, Per M. Johansson, Christer F. Nilsson, James B. Rowe, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Edwin Jabbari, Coralie Viollet, Jonathan D. Glass, Andrew B. Singleton, Vincenzo Silani, Owen A. Ross, Mina Ryten, Ali Torkamani, Toshiko Tanaka, Luigi Ferrucci, Susan M. Resnick, Stuart Pickering-Brown, Christopher B. Brady, Neil Kowal, John A. Hardy, Vivianna Van Deerlin, Jean Paul Vonsattel, Matthew B. Harms, Huw R. Morris, Raffaele Ferrari, John E. Landers, Adriano Chiò, J. Raphael Gibbs, Clifton L. Dalgard, Sonja W. Scholz, Bryan J. Traynor, Adelani Adeleye, Camille Alba, Dagmar Bacikova, Daniel N. Hupalo, Elisa McGrath Martinez, Harvey B. Pollard, Gauthaman Sukumar, Anthony R. Soltis, Meila Tuck, Xijun Zhang, Matthew D. Wilkerson, Bradley N. Smith, Nicola Ticozzi, Claudia Fallini, Athina Soragia Gkazi, Simon D. Topp, Jason Kost, Emma L. Scotter, Kevin P. Kenna, Jack W. Miller, Cinzia Tiloca, Caroline Vance, Eric W. Danielson, Claire Troakes, Claudia Colombrita, Safa Al-Sarraj, Elizabeth A. Lewis, Andrew King, Daniela Calini, Viviana Pensato, Barbara Castellotti, Jacqueline de Belleroche, Frank Baas, Anneloor L.M.A. ten Asbroek, Peter C. Sapp, Diane McKenna-Yasek, Russell L. McLaughlin, Meraida Polak, Seneshaw Asress, Jesús Esteban-Pérez, José Luis Muñoz-Blanco, Zorica Stevic, Sandra D’Alfonso, Letizia Mazzini, Giacomo P. Comi, Roberto Del Bo, Mauro Ceroni, Stella Gagliardi, Giorgia Querin, Cinzia Bertolin, Wouter van Rheenen, Frank P. Diekstra, Rosa Rademakers, Marka van Blitterswijk, Kevin B. Boylan, Giuseppe Lauria, Stefano Duga, Stefania Corti, Cristina Cereda, Lucia Corrado, Gianni Sorarù, Kelly L. Williams, Garth A. Nicholson, Ian P. Blair, Claire Leblond-Manry, Guy A. Rouleau, Orla Hardiman, Karen E. Morrison, Jan H. Veldink, Leonard H. van den Berg, Ammar Al-Chalabi, Hardev Pall, Pamela J. Shaw, Martin R. Turner, Kevin Talbot, Franco Taroni, Alberto García-Redondo, Zheyang Wu, Cinzia Gellera, Antonia Ratti, Robert H. Brown, Christopher E. Shaw, John C. Ambrose, Prabhu Arumugam, Emma L. Baple, Marta Bleda, Freya Boardman-Pretty, Jeanne M. Boissiere, Christopher R. Boustred, H. Brittain, Mark J. Caulfield, Georgia C. Chan, Clare E.H. Craig, Louise C. Daugherty, Anna de Burca, Andrew Devereau, Greg Elgar, Rebecca E. Foulger, Tom Fowler, Pedro Furió-Tarí, Joanne M. Hackett, Dina Halai, Angela Hamblin, Shirley Henderson, James E. Holman, Tim J.P. Hubbard, Rob Jackson, Louise J. Jones, Dalia Kasperaviciute, Melis Kayikci, Lea Lahnstein, Kay Lawson, Sarah E.A. Leigh, Ivonne U.S. Leong, Javier F. Lopez, Fiona Maleady-Crowe, Joanne Mason, Ellen M. McDonagh, Loukas Moutsianas, Michael Mueller, Nirupa Murugaesu, Anna C. Need, Chris A. Odhams, Christine Patch, Daniel Perez-Gil, Dimitris Polychronopoulos, John Pullinger, Tahrima Rahim, Augusto Rendon, Pablo Riesgo-Ferreiro, Tim Rogers, Kevin Savage, Kushmita Sawant, Richard H. Scott, Afshan Siddiq, Alexander Sieghart, Damian Smedley, Katherine R. Smith, Alona Sosinsky, William Spooner, Helen E. Stevens, Alexander Stuckey, Razvan Sultana, Ellen R.A. Thomas, Simon R. Thompson, Carolyn Tregidgo, Emma Walsh, Sarah A. Watters, Matthew J. Welland, Eleanor Williams, Katarzyna Witkowska, Suzanne M. Wood, Magdalena Zarowiecki, Sampath Arepalli, Pavan Auluck, Robert H. Baloh, Robert Bowser, Alexis Brice, James Broach, William Camu, John Cooper-Knock, Philippe Corcia, Carsten Drepper, Vivian E. Drory, Travis L. Dunckley, Faraz Faghri, Jennifer Farren, Eva Feldman, Mary Kay Floeter, Pietro Fratta, Glenn Gerhard, Summer B. Gibson, Stephen A. Goutman, Terry D. Heiman-Patterson, Dena G. Hernandez, Ben Hoover, Lilja Jansson, Freya Kamel, Janine Kirby, Neil W. Kowall, Hannu Laaksovirta, Francesco Landi, Isabelle Le Ber, Serge Lumbroso, Daniel JL. MacGowan, Nicholas J. Maragakis, Gabriele Mora, Kevin Mouzat, Liisa Myllykangas, Mike A. Nalls, Richard W. Orrell, Lyle W. Ostrow, Roger Pamphlett, Erik Pioro, Stefan M. Pulst, John M. Ravits, Alan E. Renton, Wim Robberecht, Ian Robey, Ekaterina Rogaeva, Jeffrey D. Rothstein, Michael Sendtner, Katie C. Sidle, Zachary Simmons, David J. Stone, Pentti J. Tienari, John Q. Trojanowski, Juan C. Troncoso, Miko Valori, Philip Van Damme, Ludo Van Den Bosch, Lorne Zinman, Diego Albani, Barbara Borroni, Alessandro Padovani, Amalia Bruni, Jordi Clarimon, Oriol Dols-Icardo, Ignacio Illán-Gala, Alberto Lleó, Adrian Danek, Daniela Galimberti, Elio Scarpini, Maria Serpente, Caroline Graff, Huei-Hsin Chiang, Behzad Khoshnood, Linn Öijerstedt, Christopher M. Morris, Benedetta Nacmias, Sandro Sorbi, Jorgen E. Nielsen, Lynne E. Hjermind, Valeria Novelli, Annibale A. Puca, Pau Pastor, Ignacio Alvarez, Monica Diez-Fairen, Miquel Aguilar, Robert Perneczky, Janine Diehl-Schimd, Mina Rossi, Agustin Ruiz, Mercè Boada, Isabel Hernández, Sonia Moreno-Grau, Johannes C. Schlachetzki, Dag Aarsland, Marilyn S. Albert, Johannes Attems, Matthew J. Barrett, Thomas G. Beach, Lynn M. Bekris, David A. Bennett, Lilah M. Besser, Eileen H. Bigio, Sandra E. Black, Bradley F. Boeve, Ryan C. Bohannan, Francesca Brett, Maura Brunetti, Chad A. Caraway, Jose-Alberto Palma, Andrea Calvo, Antonio Canosa, Dennis Dickson, Charles Duyckaerts, Kelley Faber, Tanis Ferman, Margaret E. Flanagan, Gianluca Floris, Tatiana M. Foroud, Juan Fortea, Ziv Gan-Or, Steve Gentleman, Bernardino Ghetti, Jesse Raphael Gibbs, Alison Goate, David Goldstein, Isabel González-Aramburu, Neill R. Graff-Radford, Angela K. Hodges, Heng-Chen Hu, Daniel Hupalo, Jon Infante, Alex Iranzo, Scott M. Kaiser, Horacio Kaufmann, Julia Keith, Ronald C. Kim, Gregory Klein, Rejko Krüger, Walter Kukull, Amanda Kuzma, Carmen Lage, Suzanne Lesage, James B. Leverenz, Giancarlo Logroscino, Grisel Lopez, Seth Love, Qinwen Mao, Maria Jose Marti, Elisa Martinez-McGrath, Mario Masellis, Eliezer Masliah, Patrick May, Ian McKeith, Marek-Marsel Mesulam, Edwin S. Monuki, Kathy L. Newell, Lucy Norcliffe-Kaufmann, Laura Palmer, Matthew Perkins, Olga Pletnikova, Laura Molina-Porcel, Regina H. Reynolds, Eloy Rodríguez-Rodríguez, Jonathan D. Rohrer, Pascual Sanchez-Juan, Clemens R. Scherzer, Geidy E. Serrano, Vikram Shakkottai, Ellen Sidransky, Nahid Tayebi, Alan J. Thomas, Bension S. Tilley, Ronald L. Walton, Randy Woltjer, Zbigniew K. Wszolek, Georgia Xiromerisiou, Chiara Zecca, Hemali Phatnani, Justin Kwan, Dhruv Sareen, James R. Broach, Ximena Arcila-Londono, Edward B. Lee, Neil A. Shneider, Ernest Fraenkel, Noah Zaitlen, James D. Berry, Andrea Malaspina, Gregory A. Cox, Leslie M. Thompson, Steve Finkbeiner, Efthimios Dardiotis, Timothy M. Miller, Siddharthan Chandran, Suvankar Pal, Eran Hornstein, Daniel J. MacGowan, Terry Heiman-Patterson, Molly G. Hammell, Nikolaos.A. Patsopoulos, Oleg Butovsky, Joshua Dubnau, Avindra Nath, Matt Harms, Eleonora Aronica, Mary Poss, Jennifer Phillips-Cremins, John Crary, Nazem Atassi, Dale J. Lange, Darius J. Adams, Leonidas Stefanis, Marc Gotkine, Suma Babu, Towfique Raj, Sabrina Paganoni, Ophir Shalem, Colin Smith, Bin Zhang, Brent Harris, Iris Broce, Vivian Drory, John Ravits, Corey McMillan, Vilas Menon, Lani Wu, Steven Altschuler, Khaled Amar, Neil Archibald, Oliver Bandmann, Erica Capps, Alistair Church, Jan Coebergh, Alyssa Costantini, Peter Critchley, Boyd CP. Ghosh, Michele T.M. Hu, Christopher Kobylecki, P. Nigel Leigh, Carl Mann, Luke A. Massey, Uma Nath, Nicola Pavese, Dominic Paviour, Jagdish Sharma, Jenny Vaughan, HUS Neurocenter, Neurologian yksikkö, Department of Neurosciences, Clinicum, Pentti Tienari / Principal Investigator, Parkinson's UK, Human Genetics, ARD - Amsterdam Reproduction and Development, ANS - Complex Trait Genetics, Pathology, ANS - Cellular & Molecular Mechanisms, AII - Inflammatory diseases, Universidad de Cantabria, Rowe, James [0000-0001-7216-8679], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,Huntington's Disease ,Pathology ,amyotrophic lateral sclerosis ,Huntingtin ,Neurology ,1702 Cognitive Sciences ,International ALS/FTD Genomics Consortium ,Neurodegenerative ,frontotemporal dementia ,3124 Neurology and psychiatry ,0302 clinical medicine ,Medicine ,2.1 Biological and endogenous factors ,Psychology ,Amyotrophic lateral sclerosis ,Aetiology ,Alzheimer's Disease Related Dementias (ADRD) ,NYGC ALS Consortium ,Huntingtin Protein ,DNA Repeat Expansion ,General Neuroscience ,Frontotemporal Dementia (FTD) ,International FTD Genetics Consortium ,whole-genome sequencing ,Frontotemporal Dementia ,Neurological ,Cognitive Sciences ,Lewy body dementia ,huntingtin ,repeat expansions ,Amyotrophic Lateral Sclerosis ,Humans ,Mutation ,Whole Genome Sequencing ,Frontotemporal dementia ,Huntington’s disease ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,FALS Sequencing Consortium ,Article ,03 medical and health sciences ,Atrophy ,Rare Diseases ,American Genome Center ,Clinical Research ,mental disorders ,Genetics ,Acquired Cognitive Impairment ,Dementia ,PROSPECT Consortium ,Neurology & Neurosurgery ,Lewy body ,business.industry ,International LBD Genomics Consortium ,Neurosciences ,3112 Neurosciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,nutritional and metabolic diseases ,medicine.disease ,Brain Disorders ,nervous system diseases ,030104 developmental biology ,Genomics England Research Consortium ,1701 Psychology ,ALS ,business ,1109 Neurosciences ,030217 neurology & neurosurgery - Abstract
Hannu Laaksovirta konsortion jäsenenä. The Genomics England Research Consortium, The International ALS/FTD Genomics Consortium (iAFGC), The International FTD Genetics Consortium (IFGC), The International LBD Genomics Consortium (iLBDGC), The NYGC ALS Consortium, The PROSPECT Consortium,17 James B. Rowe,17 Luisa Benussi,18 Giuliano Binetti,18,19 Roberta Ghidoni,18 Edwin Jabbari,20,21 Coralie Viollet,22 Jonathan D. Glass,23 Andrew B. Singleton,24 Vincenzo Silani,25,26 Owen A. Ross,27 Mina Ryten,8,28,29 Ali Torkamani,30 Toshiko Tanaka,31 Luigi Ferrucci,31 Susan M. Resnick,32 We examined the role of repeat expansions in the pathogenesis of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) by analyzing whole-genome sequence data from 2,442 FTD/ALS patients, 2,599 Lewy body dementia (LBD) patients, and 3,158 neurologically healthy subjects. Pathogenic expansions (range, 40?64 CAG repeats) in the huntingtin (HTT) gene were found in three (0.12%) patients diagnosed with pure FTD/ALS syndromes but were not present in the LBD or healthy cohorts. We replicated our findings in an independent collection of 3,674 FTD/ALS patients. Postmortem evaluations of two patients revealed the classical TDP-43 pathology of FTD/ALS, as well as huntingtin-positive, ubiquitin-positive aggregates in the frontal cortex. The neostriatal atrophy that pathologically defines Huntington?s disease was absent in both cases. Our findings reveal an etiological relationship between HTT repeat expansions and FTD/ALS syndromes and indicate that genetic screening of FTD/ALS patients for HTT repeat expansions should be considered. We examined the role of repeat expansions in the pathogenesis of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) by analyzing whole-genome sequence data from 2,442 FTD/ALS patients, 2,599 Lewy body dementia (LBD) patients, and 3,158 neurologically healthy subjects. Pathogenic expansions (range, 40?64 CAG repeats) in the huntingtin (HTT) gene were found in three (0.12%) patients diagnosed with pure FTD/ALS syndromes but were not present in the LBD or healthy cohorts. We replicated our findings in an independent collection of 3,674 FTD/ALS patients. Postmortem evaluations of two patients revealed the classical TDP-43 pathology of FTD/ALS, as well as huntingtin-positive, ubiquitin-positive aggregates in the frontal cortex. The neostriatal atrophy that pathologically defines Huntington?s disease was absent in both cases. Our findings reveal an etiological relationship between HTT repeat expansions and FTD/ALS syndromes and indicate that genetic screening of FTD/ALS patients for HTT repeat expansions should be considered.
- Published
- 2020
- Full Text
- View/download PDF
215. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment
- Author
-
Philip A. Barber, Thalia S. Field, M. Patrice Lindsay, Vladimir Hachinski, Aravind Ganesh, Serge Gauthier, Richard H. Swartz, Sandra E. Black, Krista L. Lanctôt, Zahinoor Ismail, Mukul Sharma, David B. Hogan, and Eric E. Smith
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Disease ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Dementia ,guidelines ,RC346-429 ,Intensive care medicine ,Vascular dementia ,Cognitive impairment ,vascular cognitive impairment ,Vascular disease ,business.industry ,Special Topic Section ,RC952-954.6 ,Consensus conference ,vascular dementia ,medicine.disease ,Hyperintensity ,Psychiatry and Mental health ,030104 developmental biology ,Blood pressure ,Geriatrics ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,dementia - Abstract
Introduction Vascular disease is a common cause of dementia, and often coexists with other brain pathologies such as Alzheimer's disease to cause mixed dementia. Many of the risk factors for vascular disease are treatable. Our objective was to review evidence for diagnosis and treatment of vascular cognitive impairment (VCI) to issue recommendations to clinicians. Methods A subcommittee of the Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD) reviewed areas of emerging evidence. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to assign the quality of the evidence and strength of the recommendations. Results Using standardized diagnostic criteria, managing hypertension to conventional blood pressure targets, and reducing risk for stroke are strongly recommended. Intensive blood pressure lowering in middle‐aged adults with vascular risk factors, using acetylsalicylic acid in persons with VCI and covert brain infarctions but not if only white matter lesions are present, and using cholinesterase inhibitors are weakly recommended. Conclusions The CCCDTD has provided evidence‐based recommendations for diagnosis and management of VCI for use nationally in Canada, that may also be of use worldwide.
- Published
- 2020
216. Distinct Cognitive and Neuroimaging Profiles in Later-Life Attention Deficit/Hyperactivity Disorder and Mild Cognitive Impairment
- Author
-
Brandy L. Callahan, Nayani Ramakrishnan, Prathiba Shammi, Daniel Bierstone, Rebecca Taylor, Miracle Ozzoude, Maged Goubran, Donalt T. Stuss, and Sandra E. Black
- Subjects
mental disorders ,behavioral disciplines and activities - Abstract
Background: Attention deficit/hyperactivity disorder (ADHD) is increasingly being recognized in adults and older adults. Some of its behavioral features (e.g., distractibility, forgetfulness, impulsivity) may resemble those of mild cognitive impairment (MCI), which contributes to diagnostic uncertainty in later life. The present study aimed to systematically compare ADHD and MCI on measures of cognition and structural neuroimaging to clarify the extent of their overlap (i.e., cognitive features of ADHD that are most likely to be taken for signs of MCI) and identify potential features unique to each disorder (i.e., that may be used to guide diagnostic impressions). Methods: One hundred and six adults aged 50 years or above were recruited from a Cognitive Neurology clinic (40 ADHD, 29 MCI and 37 controls) completed a comprehensive neuropsychological battery. A subsample (n=80) underwent structural neuroimaging.Results: Memory was impaired in both patient groups, but reflected a storage deficit in MCI (supported by imaging findings of reduced hippocampal volumes) and an encoding deficit in ADHD (supported by frontal-lobe cortical thinning). Both groups performed normally on executive measures. Semantic retrieval was uniquely impaired in MCI.Conclusions: Behavioral and structural imaging features strongly suggest that ADHD and MCI are similar manifestations of separate pathophysiological processes. Although ADHD has been proposed as a risk factor or prodromal stage of neurodegeneration, we propose it is rather acting as a phenotypic mimic of MCI via overlap in memory and executive performance.
- Published
- 2020
- Full Text
- View/download PDF
217. The impact of reporting magnetic resonance imaging incidental findings in the Canadian alliance for healthy hearts and minds cohort
- Author
-
Jean-Claude Tardif, Francois Marcotte, Sonia S. Anand, Dipika Desai, Ma'n H. Zawati, Erika Kleiderman, Sandra E. Black, Bartha Maria Knoppers, Anand K. Sergeant, Alan R. Moody, Judy M. Luu, Eric E. Smith, Karleen M. Schulze, Matthias G. Friedrich, Douglas S. Lee, and Eric Larose
- Subjects
Male ,Quality of life ,Canada ,Health (social science) ,Medical philosophy. Medical ethics ,media_common.quotation_subject ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Life insurance ,Medicine ,Humans ,030212 general & internal medicine ,Justice (ethics) ,media_common ,Aged ,Response rate (survey) ,Ethics ,Incidental Findings ,R723-726 ,business.industry ,Health Policy ,Brain ,Middle Aged ,Magnetic Resonance Imaging ,3. Good health ,Clinical trial ,Issues, ethics and legal aspects ,Philosophy of medicine ,Cohort ,Female ,business ,Autonomy ,Clinical psychology ,Research Article - Abstract
Background In the Canadian Alliance for Healthy Hearts and Minds (CAHHM) cohort, participants underwent magnetic resonance imaging (MRI) of the brain, heart, and abdomen, that generated incidental findings (IFs). The approach to managing these unexpected results remain a complex issue. Our objectives were to describe the CAHHM policy for the management of IFs, to understand the impact of disclosing IFs to healthy research participants, and to reflect on the ethical obligations of researchers in future MRI studies. Methods Between 2013 and 2019, 8252 participants (mean age 58 ± 9 years, 54% women) were recruited with a follow-up questionnaire administered to 909 participants (40% response rate) at 1-year. The CAHHM policy followed a restricted approach, whereby routine feedback on IFs was not provided. Only IFs of severe structural abnormalities were reported. Results Severe structural abnormalities occurred in 8.3% (95% confidence interval 7.7–8.9%) of participants, with the highest proportions found in the brain (4.2%) and abdomen (3.1%). The majority of participants (97%) informed of an IF reported no change in quality of life, with 3% of participants reporting that the knowledge of an IF negatively impacted their quality of life. Furthermore, 50% reported increased stress in learning about an IF, and in 95%, the discovery of an IF did not adversely impact his/her life insurance policy. Most participants (90%) would enrol in the study again and perceived the MRI scan to be beneficial, regardless of whether they were informed of IFs. While the implications of a restricted approach to IF management was perceived to be mostly positive, a degree of diagnostic misconception was present amongst participants, indicating the importance of a more thorough consent process to support participant autonomy. Conclusion The management of IFs from research MRI scans remain a challenging issue, as participants may experience stress and a reduced quality of life when IFs are disclosed. The restricted approach to IF management in CAHHM demonstrated a fair fulfillment of the overarching ethical principles of respect for autonomy, concern for wellbeing, and justice. The approach outlined in the CAHHM policy may serve as a framework for future research studies. Clinical trial registrationhttps://clinicaltrials.gov/ct2/show/NCT02220582.
- Published
- 2020
218. Trial of remote ischaemic preconditioning in vascular cognitive impairment (TRIC-VCI): protocol
- Author
-
Zahinoor Ismail, Mukul Sharma, Richard Frayne, Dale Corbett, Vladimir Hachinski, Demetrios J. Sahlas, Cheryl R. McCreary, Eric E. Smith, Thalia S. Field, Lauren M. Mai, Sandra E. Black, Richard H. Swartz, Philip A. Barber, and Aravind Ganesh
- Subjects
medicine.medical_specialty ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Randomized controlled trial ,law ,Ischemia ,medicine ,Dementia ,Humans ,Cognitive Dysfunction ,Ischemic Preconditioning ,Stroke ,Aged ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,clinical trials ,business.industry ,Montreal Cognitive Assessment ,General Medicine ,Middle Aged ,medicine.disease ,stroke ,Hyperintensity ,3. Good health ,Clinical trial ,Tolerability ,Cerebral blood flow ,Neurology ,Physical therapy ,Medicine ,business ,030217 neurology & neurosurgery ,dementia - Abstract
IntroductionCerebral small vessel disease (cSVD) accounts for 20%–25% of strokes and is the most common cause of vascular cognitive impairment (VCI). In an animal VCI model, inducing brief periods of limb ischaemia-reperfusion reduces subsequent ischaemic brain injury with remote and local protective effects, with hindlimb remote ischaemic conditioning (RIC) improving cerebral blood flow, decreasing white-matter injury and improving cognition. Small human trials suggest RIC is safe and may prevent recurrent strokes. It remains unclear what doses of chronic daily RIC are tolerable and safe, whether effects persist after treatment cessation, and what parameters are optimal for treatment response.Methods and analysisThis prospective, open-label, randomised controlled trial (RCT) with blinded end point assessment and run-in period, will recruit 24 participants, randomised to one of two RIC intensity groups: one arm treated once daily or one arm twice daily for 30 consecutive days. RIC will consistent of 4 cycles of blood pressure cuff inflation to 200 mm Hg for 5 min followed by 5 min deflation (total 35 min). Selection criteria include: age 60–85 years, evidence of cSVD on brain CT/MRI, Montreal Cognitive Assessment (MoCA) score 13–24 and preserved basic activities of living. Outcomes will be assessed at 30 days and 90 days (60 days after ceasing treatment). The primary outcome is adherence (completing ≥80% of sessions). Secondary safety/tolerability outcomes include the per cent of sessions completed and pain/discomfort scores from patient diaries. Efficacy outcomes include changes in cerebral blood flow (per arterial spin-label MRI), white-matter hyperintensity volume, diffusion tensor imaging, MoCA and Trail-Making tests.Ethics and disseminationResearch Ethics Board approval has been obtained. The results will provide information on feasibility, dose, adherence, tolerability and outcome measures that will help design a phase IIb RCT of RIC, with the potential to prevent VCI. Results will be disseminated through peer-reviewed publications, organisations and meetings.Trial registration numberNCT04109963.
- Published
- 2020
219. Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study
- Author
-
Alan R. Moody, Matthias G. Friedrich, Sonia S. Anand, Hertzel C. Gerstein, Douglas S. Lee, Jason Hicks, Jean-Claude Tardif, Jennifer E. Vena, Philippe Broët, Trevor J.B. Dummer, Sandra E. Black, Philip Awadalla, Koon K. Teo, Salim Yusuf, Chinthanie Ramasundarahettige, Dipika Desai, and Eric E. Smith
- Subjects
Adult ,Brain Infarction ,Male ,medicine.medical_specialty ,Canada ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Neuroimaging ,030204 cardiovascular system & hematology ,Neuropsychological Tests ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Risk Factors ,Diabetes mellitus ,Internal medicine ,medicine ,Diabetes Mellitus ,Prevalence ,Humans ,Cognitive Dysfunction ,Risk factor ,Online Only articles ,Stroke ,Aged ,business.industry ,Microcirculation ,Biochemistry (medical) ,Montreal Cognitive Assessment ,Brain ,Odds ratio ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Confidence interval ,3. Good health ,Cognitive test ,Cerebrovascular Disorders ,Cross-Sectional Studies ,Digit symbol substitution test ,Cardiology ,Female ,business ,030217 neurology & neurosurgery - Abstract
Background Diabetes is a risk factor for cerebrovascular disease and cognitive impairment. The anatomical basis for this is uncertain. Methods The Canadian Alliance for Healthy Hearts and Minds collected brain and carotid magnetic resonance imaging (MRI) and 2 cognitive tests (the Digit Symbol Substitution Test and the Montreal Cognitive Assessment test) in a cross-sectional sample of men and women. Brain MRIs identified brain infarcts (BI), lacunar BI, high white matter hyperintensity (WMH), vascular brain injury (VBI; BI or high WMH), and small vessel VBI (lacunar BI or high WMH). Carotid MRIs estimated carotid wall volume, a measure of subclinical atherosclerosis. Cognitive scores were standardized to each site’s mean score, and cognitive impairment was identified by 1 or both test scores ≤1 standard deviation below the site’s mean score on that test. Results The 7733 participants included 495 participants (6.4%) with diabetes, of whom 388 were taking diabetes drugs. After age and sex adjustment, diabetes was independently associated with BI (odds ratio [OR] 1.53, 95% confidence interval [CI] 1.05, 2.24), VBI (OR 1.64, 95% CI 1.26, 2.13), small vessel VBI (OR 1.67, 95% CI 1.28, 2.19), and cognitive impairment (OR 1.47, 95% CI 1.20, 1.80). The association between diabetes and small vessel VBI persisted after adjustment for cerebrovascular disease risk factors and nonlacunar infarcts (OR 1.52, 95% CI 1.15, 2.01), and the association with cognitive impairment persisted after adjustment for small vessel VBI (OR 1.27, 95% CI 1.03, 1.56). Conclusion Small vessel disease characterizes much of the relationship between diabetes and VBI. However, additional factors are required to disentangle the relationship between diabetes and cognitive impairment.
- Published
- 2020
220. Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI
- Author
-
Susan Rotzinger, Piali Bhati, Pradeep Reddy Raamana, Nuwan D. Nanayakkara, Robert Bartha, Athena E. Theyers, Glenda MacQueen, Jacqueline K. Harris, Raymond W. Lam, Daniel J. Müller, Mojdeh Zamyadi, Stephen C. Strother, Benicio N. Frey, Roumen Milev, Sean P. Symons, Stephen R. Arnott, Mario Masellis, Stefanie Hassel, Anthony E. Lang, Sandra E. Black, Christopher J.M. Scott, Tharushan Selliah, and Sidney H. Kennedy
- Subjects
Visual inspection ,Protocol (science) ,Neuroimaging ,business.industry ,Computer science ,media_common.quotation_subject ,Pattern recognition ,Quality (business) ,Artificial intelligence ,business ,Reliability (statistics) ,media_common - Abstract
Quality control of morphometric neuroimaging data is essential to improve reproducibility. Owing to the complexity of neuroimaging data and subsequently the interpretation of their results, visual inspection by trained raters is the most reliable way to perform quality control. Here, we present a protocol for visual quality control of the anatomical accuracy of FreeSurfer parcellations, based on an easy-to-use open source tool called VisualQC. We comprehensively evaluate its utility in terms of error detection rate and inter-rater reliability on two large multi-site datasets, and discuss site differences in error patterns. This evaluation shows that VisualQC is a practically viable protocol for community adoption.
- Published
- 2020
- Full Text
- View/download PDF
221. Thickness of the cerebral cortex shows positive association with blood levels of triacylglycerols carrying 18-carbon fatty acids
- Author
-
Jean Shin, Sandra E. Black, Sudha Seshadri, Tomáš Paus, Eeva Sliz, Zdenka Pausova, and Catriona Syme
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Linoleic acid ,Medicine (miscellaneous) ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,chemistry.chemical_compound ,Cognition ,0302 clinical medicine ,Internal medicine ,Lipidomics ,medicine ,Humans ,Metabolomics ,Cognitive decline ,lcsh:QH301-705.5 ,Triglycerides ,Cerebral Cortex ,chemistry.chemical_classification ,Fatty Acids ,food and beverages ,Fatty acid ,Organ Size ,Metabolism ,Middle Aged ,Magnetic Resonance Imaging ,030104 developmental biology ,medicine.anatomical_structure ,Endocrinology ,lcsh:Biology (General) ,chemistry ,Cerebral cortex ,Docosahexaenoic acid ,Metabolome ,Female ,lipids (amino acids, peptides, and proteins) ,Arachidonic acid ,General Agricultural and Biological Sciences ,Biomarkers ,030217 neurology & neurosurgery ,Neuroscience - Abstract
Perturbations in fatty acid (FA) metabolism as well as thinning of the cerebral cortex have been associated with cognitive decline in the elderly. Predominant FAs in the brain are docosahexaenoic acid (DHA) and arachidonic acid (ARA). Approximately 2–8% of esterified DHA and 3–5% of esterified ARA in the brain are replaced daily. DHA and ARA are derivatives of 18-carbon essential FAs, α-linolenic acid and linoleic acid, that must be imported into the brain from the circulation. In blood, FAs are primarily transported in triacylglycerols (TAGs) from which they can be released at the blood–brain-barrier and transported inside the brain. We show that circulating levels of TAGs carrying 18-carbon FAs are positively associated with cortical thickness in middle-aged adults. These associations are stronger in cortical regions with higher expression of genes regulating long-chain FA metabolism and cellular membranes, and cortical thickness in the same regions may be related to cognitive performance., Eeva Sliz et al. show an association between triacylglycerols species carrying 18-carbon unsaturated fatty acids and cortical thickness by combining serum lipidomics and brain imaging data. This association is more pronounced in cortical regions with higher expression of genes regulating fatty acid metabolism and cellular membranes.
- Published
- 2020
- Full Text
- View/download PDF
222. Cortical thickness estimation in individuals with cerebral small vessel disease, focal atrophy, and chronic stroke lesions
- Author
-
Donna Kwan, Joel Ramirez, Maria Carmela Tartaglia, Brian Tan, Kirstin Walker, Robert Bartha, Maged Goubran, Pradeep Reddy Raamana, Christopher J.M. Scott, Miracle Ozzoude, Stephen C. Strother, Sean P. Symons, Sandra E. Black, Richard H. Swartz, Melissa F. Holmes, and Derek Beaton
- Subjects
medicine.medical_specialty ,business.industry ,Focal atrophy ,Montreal Cognitive Assessment ,Disease ,Neurovascular bundle ,medicine.disease ,White matter ,Atrophy ,medicine.anatomical_structure ,Neuroimaging ,medicine ,Radiology ,business ,Stroke - Abstract
BackgroundRegional changes to cortical thickness in individuals with neurodegenerative and cerebrovascular diseases can be estimated using specialised neuroimaging software. However, the presence of cerebral small vessel disease, focal atrophy, and cortico-subcortical stroke lesions, pose significant challenges that increase the likelihood of misclassification errors and segmentation failures.PurposeThe main goal of this study was to examine a correction procedure developed for enhancing FreeSurfer’s cortical thickness estimation tool, particularly when applied to the most challenging MRI obtained from participants with chronic stroke and cerebrovascular disease, with varying degrees of neurovascular lesions and brain atrophy.MethodsIn 155 cerebrovascular disease patients enrolled in the Ontario Neurodegenerative Disease Research Initiative (ONDRI), FreeSurfer outputs were compared between a fully automated, unmodified procedure and a corrected procedure that accounted for potential sources of error due to atrophy and neurovascular lesions. Quality control (QC) measures were obtained from both procedures. Association between cortical thickness and global cognitive status as assessed by the Montreal Cognitive Assessment (MoCA) score was also investigated from both procedures.ResultsCorrected procedures increased ‘Acceptable’ QC ratings from 18% to 76% for the cortical ribbon and from 38% to 92% for tissue segmentation. Corrected procedures reduced ‘Fail’ ratings from 11% to 0% for the cortical ribbon and 62% to 8% for tissue segmentation. FreeSurfer-based segmentation of T1-weighted white matter hypointensities were significantly greater in the corrected procedure (5.8mL vs. 15.9mL, pConclusionsThese findings suggest that correction procedures that account for brain atrophy and neurovascular lesions can significantly improve FreeSurfer’s segmentation results, reduce failure rates, and potentially increase sensitivity to examine brain-behaviour relationships. Future work will examine relationships between cortical thickness, cerebral small vessel disease, and neurodegenerative disease in the ONDRI study.
- Published
- 2020
- Full Text
- View/download PDF
223. The Ontario Neurodegenerative Disease Research Initiative
- Author
-
Lorne Zinman, Michael J. Strong, Paula M. McLaughlin, Julia Fraser, Andrew Frank, Stephen H. Pasternak, Malcolm A. Binns, Angela Roberts, Mandar Jog, Dar Dowlatshahi, Demetrios J. Sahlas, Ayman Hassan, Jennifer Mandzia, Robert A. Hegele, Sandra E. Black, Leanne K. Casaubon, Angela K. Troyer, David G. Munoz, Thomas Steeves, Frederico Pieruccini-Faria, Wendy Lou, Joel Ramirez, Kelly M Sunderland, Ondri Investigators, Manuel Montero-Odasso, Connie Marras, Robert Bartha, Christopher Hudson, Christen Shoesmith, Michael Borrie, Donna Kwan, Morris Freedman, Maria Carmela Tartaglia, David F. Tang-Wai, David S. Park, Allison A Dilliott, Benjamin Cornish, Ekaterina Rogaeva, Donald C. Brien, Tarek K. Rajji, Stephen C. Strother, Sean P. Symons, Stephen R. Arnott, Mario Masellis, David Grimes, Sanjeev Kumar, John Turnbull, Wendy Hatch, Anthony E. Lang, Brian C. Coe, Douglas P. Munoz, Brian Levine, Elizabeth Finger, Peter W. Kleinstiver, Corinne E. Fischer, Brian Tan, Christopher J.M. Scott, Jane M. Lawrence-Dewar, William E. McIlroy, Dallas Seitz, Derek Beaton, Richard H. Swartz, Joseph B. Orange, John F. Robinson, Barry D. Greenberg, and Gustavo Saposnik
- Subjects
Gerontology ,business.industry ,Cohort ,medicine ,Neuropsychology ,Montreal Cognitive Assessment ,Cognition ,Disease ,Amyotrophic lateral sclerosis ,medicine.disease ,business ,Frontotemporal dementia ,Cohort study - Abstract
ObjectiveIn individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results.MethodsFive disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics.Results520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location.ConclusionONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.
- Published
- 2020
- Full Text
- View/download PDF
224. Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario Neurodegenerative Disease Research Initiative
- Author
-
Stephen C. Strother, Michael Borrie, Morris Freedman, David Grimes, Joseph B. Orange, Sanjeev Kumar, Tarek K. Rajji, Gustavo Saposnik, Demetrios J. Sahlas, Malcolm A. Binns, Elizabeth Finger, Paula M. McLaughlin, Douglas P. Munoz, Lorne Zinman, Carmela Tartaglia, Corinne E. Fischer, Jennifer Mandzia, Derek Beaton, Joel Ramirez, Kelly M Sunderland, Richard H. Swartz, Angela Roberts, Ayman Hassan, Connie Marras, Dallas Seitz, Lang Ae, Sandra E. Black, Dariush Dowlatshahi, Bruce G. Pollock, Agessandro Abrahao, Mario Masellis, Kwan D, Tan B, Angela K. Troyer, John Turnbull, Christopher J.M. Scott, Brian Levine, David F. Tang-Wai, David P. Breen, and Andrew Frank
- Subjects
Gerontology ,Text mining ,business.industry ,Psychology ,business - Abstract
Objectives: In the Ontario Neurodegenerative Disease Research Initiative (ONDRI), we aimed to ask and answer: (1) How many and what types of burdens are captured by the Zarit’s Burden Interview (ZBI)? (2) Do we see categorical or spectrum-like effects for burden(s)? and (3) Which if any demographic, clinical, and cognitive measures are related to burden(s)?Methods: N = 504 participants and their study partners (e.g., family, friends) across: Alzheimer’s disease/mild cognitive impairment (AD/MCI; n = 120), Parkinson’s disease (PD; n = 136), amyotrophic lateral sclerosis (ALS; n = 38), frontotemporal dementia (FTD; n = 53), and cerebrovascular disease (CVD; n = 157). Study partners provided information about themselves, and information about the clinical participants (e.g., activities of daily living). We used Correspondence Analysis to identify types of caregiving concerns in the ZBI, then identified relationships between those concerns and demographic and clinical measures, and a cognitive battery.Results: We found three components in the ZBI. The first was “overall burden” and was (1) strongly related to increased neuropsychiatric symptoms and decreased independence in activities of daily living, (2) moderately related to cognition, and (3) showed little-to-no differences between disorders. The second and third components showed four types of caregiving concerns: current care of patient, future care of patient, personal concerns of study partner, and social concerns of study partner. Discussion: Caregiving concerns are individual experiences and emphasize the importance of support for management of activities of daily living and neuropsychiatric symptoms, and underscore individualized needs for caregiving assessment and education.
- Published
- 2020
- Full Text
- View/download PDF
225. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture
- Author
-
Pentti J. Tienari, James B. Leverenz, Nahid Tayebi, Gabriele Mora, Bradley F. Boeve, Laura Palmer, Steve M. Gentleman, Ellen Sidransky, Pau Pastor, Liana S. Rosenthal, G. Xiromerisiou, Sara Saez-Atienzar, Francesco Landi, Scott M. Kaiser, Qinwen Mao, Claire Troakes, Peter St George-Hyslop, Andrea Calvo, Suzanne Lesage, Mario Masellis, Randy Woltjer, Marilyn S. Albert, Thomas T. Warner, Lorraine N. Clark, Gregory Klein, Charles Duyckaerts, Seth Love, Ed Monuki, Lawrence S. Honig, Kelley Faber, Dennis W. Dickson, Lucy Norcliffe-Kaufmann, Cornelis Blauwendraat, Ronald C. Kim, Kevin Morgan, Clifton L. Dalgard, Joshua T. Geiger, Ali Torkamani, Jinhui Ding, Juan Fortea, Eliezer Masliah, Ekaterina Rogaeva, Matthew H. Perkins, Clemens R. Scherzer, John Q. Trojanowski, Zbigniew K. Wszolek, Glenda M. Halliday, Jordi Clarimón, Sonja W. Scholz, Olaf Ansorge, Makayla K. Portley, Toshiko Tanaka, Mary B. Makarious, Safa Al-Sarraj, Giancarlo Logroscino, John D. Eicher, Neill R. Graff-Radford, Carmen Lage, Ziv Gan-Or, Francesca Brett, Alison Goate, Raffaele Ferrari, John C. Morris, J. Raphael Gibbs, Lynn M. Bekris, Jose-Alberto Palma, Angela K. Hodges, Regina H. Reynolds, Alexis Brice, Monica Diez-Fairen, Coralie Viollet, Patrick May, Minna Oinas, Erika Salvi, Vivianna M. Van Deerlin, Estrella Morenas-Rodríguez, Anni Moore, Zane Jaunmuktane, Eileen H. Bigio, Daniele Cusi, Douglas Galasko, Ruth Chia, Kathy L. Newell, Isabel Santana, Claudia Schulte, David Goldstein, Thomas Gasser, Owen A. Ross, Walter A. Kukull, Tatiana Foroud, Chad A. Caraway, David A. Bennett, Samreen Ahmed, Lilah M. Besser, Antonio Canosa, Daniel Alcolea, Yevgeniya Abramzon, Elisabet Londos, Laura Parkkinen, Sandra E. Black, Eric Topol, Marya S. Sabir, Olga Pletnikova, Grisel Lopez, Tanis J. Ferman, Johannes Attems, Matthew J. Barrett, Margaret E. Flanagan, Horacio Kaufmann, Stuart Pickering Brown, Jon Infante, Ryan C. Bohannan, Alberto Lleó, Eloy Rodríguez-Rodríguez, Huw R. Morris, Gianluca Floris, Ted M. Dawson, Maura Brunetti, Alan E. Renton, Andrew B. Singleton, Karen Marder, Alan J. Thomas, Pascual Sanchez-Juan, Adriano Chiò, Nigel J. Cairns, David J. Stone, Tammaryn Lashley, Mike A. Nalls, Bernardino Ghetti, Sara Bandres-Ciga, Zalak Shah, Ian G. McKeith, Susan M. Resnick, Julia Keith, Liisa Myllykangas, Diego Albani, Christopher M. Morris, Vikram Shakkottai, M. Ryten, Ronald L. Walton, Isabel González-Aramburu, Luigi Ferrucci, Bryan J. Traynor, Amanda B. Kuzma, Afina W. Lemstra, Thomas G. Beach, Juan C. Troncoso, Emil K. Gustavsson, Maurizio Grassano, John Hardy, Geidy E. Serrano, Rejko Krüger, Dag Aarsland, Bension S. Tilley, and Dena G. Hernandez
- Subjects
0303 health sciences ,Lewy body ,Disease ,Computational biology ,Biology ,medicine.disease ,DNA sequencing ,Genetic architecture ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Dementia ,Genetic risk ,Gene ,030217 neurology & neurosurgery ,030304 developmental biology ,Genetic association - Abstract
The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed whole-genome sequencing in large cohorts of LBD cases and neurologically healthy controls to study the genetic architecture of this understudied form of dementia and to generate a resource for the scientific community. Genome-wide association analysis identified five independent risk loci, whereas genome-wide gene-aggregation tests implicated mutations in the gene GBA. Genetic risk scores demonstrate that LBD shares risk profiles and pathways with Alzheimer’s and Parkinson’s disease, providing a deeper molecular understanding of the complex genetic architecture of this age-related neurodegenerative condition.
- Published
- 2020
- Full Text
- View/download PDF
226. Macular thickness and peripapillary RNFL thickness in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)
- Author
-
Wendy Hatch, Maria Carmela Tartaglia, Morris Freedman, Mario Masellis, Malcolm Binns, Hyejung Jung, Wendy Lou, Brian Tan, Lorne Zinman, David Tang-Wai, Sandra E. Black, Elizabeth Finger, Edward Margolin, Efrem D. Mandelcorn, Saba Samet, Faryan Tayyari, Emily Snook, Christopher Hudson, and Bryan Wong
- Published
- 2020
- Full Text
- View/download PDF
227. Determining Corticospinal Tract Injury from Stroke Using Computed Tomography
- Author
-
Sandra E. Black, George Mochizuki, Joyce L. Chen, Gregory M. Szilagyi, Timothy K. Lam, Fuqiang Gao, Daniel K. Cheung, and Seth A. Climans
- Subjects
medicine.medical_specialty ,Pyramidal Tracts ,Computed tomography ,030204 cardiovascular system & hematology ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Stroke ,Acute stroke ,medicine.diagnostic_test ,business.industry ,Brain ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Neurology ,Corticospinal tract ,Biomarker (medicine) ,Motor recovery ,Neurology (clinical) ,Radiology ,medicine.symptom ,business ,Tomography, X-Ray Computed ,030217 neurology & neurosurgery - Abstract
Introduction:Damage to the corticospinal tract (CST) from stroke leads to motor deficits. The damage can be quantified as the amount of overlap between the stroke lesion and CST (CST Injury). Previous literature has shown that the degree of motor deficits post-stroke is related to the amount of CST Injury. These studies delineate the stroke lesion from structural T1-weighted magnetic resonance imaging (MRI) scans, often acquired for research. In Canada, computed tomography (CT) is the most common imaging modality used in routine acute stroke care. In this proof-of-principle study, we determine whether CST Injury, using lesions delineated from CT scans, significantly explains the variability in motor impairment in individuals with stroke.Methods:Thirty-seven participants with stroke were included in this study. These individuals had a CT scan within the acute stage (7 days) of their stroke and underwent motor assessments. Brain images from CT scans were registered to MRI space. We performed a stepwise regression analysis to determine the contribution of CST injury and demographic variables in explaining motor impairment variability.Results:Using clinically available CT scans, we found modest evidence that CST Injury explains variability in motor impairment (R2adj = 0.12, p = 0.02). None of the participant demographic variables entered the model.Conclusion:We show for the first time a relationship between CST Injury and motor impairment using CT scans. Further work is required to evaluate the utility of data derived from clinical CT scans as a biomarker of stroke motor recovery.
- Published
- 2020
228. A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease
- Author
-
Maurits A. Jansen, Joanna M. Wardlaw, Joel Ramirez, Rosalind Brown, Ian Marshall, Axel Montagne, Hedok Lee, Michael S. Stringer, Mikko T Huuskonen, Sarah Atwi, Helene Benveniste, Berislav V. Zlokovic, Bradley J. MacIntosh, and Sandra E. Black
- Subjects
Rodentia ,Brain imaging ,Disease ,Review Article ,030218 nuclear medicine & medical imaging ,Translational Research, Biomedical ,03 medical and health sciences ,Lacunar infarcts ,0302 clinical medicine ,Neuroimaging ,medicine ,Effective treatment ,Animals ,Humans ,Histological examination ,medicine.diagnostic_test ,business.industry ,General Neuroscience ,Magnetic resonance imaging ,Systematic reviews ,Magnetic Resonance Imaging ,3. Good health ,Small vessel disease ,Lacunar Infarcts ,Cerebrovascular Disorders ,Disease Models, Animal ,Microvessels ,Dementia ,Neurology (clinical) ,Small vessel ,Cardiology and Cardiovascular Medicine ,business ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Cerebral small vessel disease (SVD) is a major health burden, yet the pathophysiology remains poorly understood with no effective treatment. Since much of SVD develops silently and insidiously, non-invasive neuroimaging such as MRI is fundamental to detecting and understanding SVD in humans. Several relevant SVD rodent models are established for which MRI can monitor in vivo changes over time prior to histological examination. Here, we critically review the MRI methods pertaining to salient rodent models and evaluate synergies with human SVD MRI methods. We found few relevant publications, but argue there is considerable scope for greater use of MRI in rodent models, and opportunities for harmonisation of the rodent-human methods to increase the translational potential of models to understand SVD in humans. We summarise current MR techniques used in SVD research, provide recommendations and examples and highlight practicalities for use of MRI SVD imaging protocols in pre-selected, relevant rodent models. Electronic supplementary material The online version of this article (10.1007/s12975-020-00843-8) contains supplementary material, which is available to authorised users.
- Published
- 2020
- Full Text
- View/download PDF
229. The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score
- Author
-
Sandra E. Black, Demetrios J. Sahlas, Maged Goubran, Michael D. Noseworthy, Jean-Paul Soucy, Vesna Sossi, Alexander Thiel, Katherine Zukotynski, Robin Hsiung, Vincent Gaudet, Frank S. Prato, Jean-Claude Tardif, Phillip H. Kuo, Robert Laforce, Howard Chertkow, Christian Bocti, Christopher J.M. Scott, Michael Borrie, Sabrina Adamo, Richard Frayne, and Eric E. Smith
- Subjects
Male ,medicine.medical_specialty ,Amyloid ,Lacunar stroke ,Cerebellar Gray Matter ,030218 nuclear medicine & medical imaging ,White matter ,Machine Learning ,03 medical and health sciences ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,mental disorders ,Image Processing, Computer-Assisted ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Cognitive impairment ,Aged ,Aniline Compounds ,medicine.diagnostic_test ,business.industry ,Montreal Cognitive Assessment ,Brain ,General Medicine ,Middle Aged ,medicine.disease ,Random forest ,medicine.anatomical_structure ,nervous system ,Positron emission tomography ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Ethylene Glycols ,Female ,Radiology ,Alzheimer's disease ,business - Abstract
Purpose The aim of this study was to evaluate random forests (RFs) to identify ROIs on F-florbetapir and F-FDG PET associated with Montreal Cognitive Assessment (MoCA) score. Materials and methods Fifty-seven subjects with significant white matter disease presenting with either transient ischemic attack/lacunar stroke or mild cognitive impairment from early Alzheimer disease, enrolled in a multicenter prospective observational trial, had MoCA and F-florbetapir PET; 55 had F-FDG PET. Scans were processed using the MINC toolkit to generate SUV ratios, normalized to cerebellar gray matter (F-florbetapir PET), or pons (F-FDG PET). SUV ratio data and MoCA score were used for supervised training of RFs programmed in MATLAB. Results F-Florbetapir PETs were randomly divided into 40 training and 17 testing scans; 100 RFs of 1000 trees, constructed from a random subset of 16 training scans and 20 ROIs, identified ROIs associated with MoCA score: right posterior cingulate gyrus, right anterior cingulate gyrus, left precuneus, left posterior cingulate gyrus, and right precuneus. Amyloid increased with decreasing MoCA score. F-FDG PETs were randomly divided into 40 training and 15 testing scans; 100 RFs of 1000 trees, each tree constructed from a random subset of 16 training scans and 20 ROIs, identified ROIs associated with MoCA score: left fusiform gyrus, left precuneus, left posterior cingulate gyrus, right precuneus, and left middle orbitofrontal gyrus. F-FDG decreased with decreasing MoCA score. Conclusions Random forests help pinpoint clinically relevant ROIs associated with MoCA score; amyloid increased and F-FDG decreased with decreasing MoCA score, most significantly in the posterior cingulate gyrus.
- Published
- 2020
230. Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging-Detected Vascular Brain Injury
- Author
-
Jonathan Leipsic, Salim Yusuf, Eric E. Smith, David Kelton, Grace Parraga, Louise Parker, Karleen M. Schulze, Anish Kirpalani, Jean-Claude Tardif, David Busseuil, Paul Poirier, Minds Cohort, Philip Awadalla, Paula J. Robson, Dipika Desai, Sébastien Jacquemont, Sandra E. Black, Sonia S. Anand, Alan R. Moody, Koon K. Teo, Trevor J.B. Dummer, Jennifer E. Vena, Scott A. Lear, Matthias G. Friedrich, Alexander Dick, and Michael D. Noseworthy
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population ,Cohort Studies ,Internal medicine ,Medicine ,Humans ,Cognitive Dysfunction ,Myocardial infarction ,Prospective Studies ,education ,Stroke ,Aged ,Advanced and Specialized Nursing ,education.field_of_study ,Framingham Risk Score ,medicine.diagnostic_test ,business.industry ,Montreal Cognitive Assessment ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,Mental Status and Dementia Tests ,Magnetic Resonance Imaging ,Hyperintensity ,Brain Injuries ,Attributable risk ,Cardiology ,brain ,cardiovascular disease ,cognition ,infarction ,risk factors ,Medical Biophysics ,Female ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and Purpose— Little is known about the association between covert vascular brain injury and cognitive impairment in middle-aged populations. We investigated if scores on a cognitive screen were lower in individuals with higher cardiovascular risk, and those with covert vascular brain injury. Methods— Seven thousand five hundred forty-seven adults, aged 35 to 69 years, free of cardiovascular disease underwent a cognitive assessment using the Digital Symbol Substitution test and Montreal Cognitive Assessment, and magnetic resonance imaging (MRI) to detect covert vascular brain injury (high white matter hyperintensities, lacunar, and nonlacunar brain infarctions). Cardiovascular risk factors were quantified using the INTERHEART (A Global Study of Risk Factors for Acute Myocardial Infarction) risk score. Multivariable mixed models tested for independent determinants of reduced cognitive scores. The population attributable risk of risk factors and MRI vascular brain injury on low cognitive scores was calculated. Results— The mean age of participants was 58 (SD, 9) years; 55% were women. Montreal Cognitive Assessment and Digital Symbol Substitution test scores decreased significantly with increasing age ( P P Conclusions— Among a middle-aged community-dwelling population, scores on a cognitive screen were lower in individuals with higher cardiovascular risk factors or MRI vascular brain injury. Much of the population attributable risk of low cognitive scores can be attributed to lower educational attainment, higher cardiovascular risk factors, and MRI vascular brain injury.
- Published
- 2020
231. Winners and Losers? The Effect of Gaining and Losing Access to Selective Colleges on Education and Labor Market Outcomes
- Author
-
Jeffrey T. Denning, Jesse Rothstein, and Sandra E. Black
- Subjects
ComputingMilieux_THECOMPUTINGPROFESSION ,Earnings ,ComputingMilieux_COMPUTERSANDEDUCATION ,Equity (finance) ,Demographic economics ,Business ,College enrollment ,Graduation - Abstract
Selective college admissions are fundamentally a question of tradeoffs: Given capacity, admitting one student means rejecting another. Research to date has generally estimated average effects of college selectivity, and has been unable to distinguish between the effects on students gaining access and on those losing access under alternative admissions policies. We use the introduction of the Top Ten Percent rule and administrative data from the State of Texas to estimate the effect of access to a selective college on student graduation and earnings outcomes. We estimate separate effects on two groups of students. The first--highly ranked students at schools which previously sent few students to the flagship university--gain access due to the policy; the second--students outside the top tier at traditional “feeder” high schools--tend to lose access. We find that students in the first group see increases in college enrollment and graduation with some evidence of positive earnings gains 7-9 years after college. In contrast, students in the second group attend less selective colleges but do not see declines in overall college enrollment, graduation, or earnings. The Top Ten Percent rule, introduced for equity reasons, thus also seems to have improved efficiency.
- Published
- 2020
- Full Text
- View/download PDF
232. Embolic Stroke of Undetermined Source and Sleep Disorders
- Author
-
Mark I. Boulos, Brian J. Murray, Laavanya Dharmakulaseelan, Sandra E. Black, Richard H. Swartz, and Nathan Chan-Smyth
- Subjects
Male ,Sleep Wake Disorders ,medicine.medical_specialty ,Embolism ,Polysomnography ,030204 cardiovascular system & hematology ,Brain Ischemia ,Brain ischemia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Stroke ,Aged ,Advanced and Specialized Nursing ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Sleep apnea ,Middle Aged ,medicine.disease ,Sleep in non-human animals ,Pathophysiology ,Embolic stroke ,Obstructive sleep apnea ,Cardiology ,Female ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery - Abstract
Background and Purpose— Compared with other causes of ischemic stroke, the mechanism of action of embolic stroke of undetermined source (ESUS) remains unclear, with previous literature suggesting that ESUS may be due to an undetected cardioembolic source. This study aimed to improve our understanding of the pathophysiology of ESUS through current knowledge of sleep disorders. Methods— Patients were included in this study if they sustained an ischemic stroke and completed either polysomnography or a home sleep apnea test. Strokes were classified into 1 of 6 mechanisms and were compared with the presence of sleep disorders (ie, obstructive sleep apnea, periodic limb movements, and abnormalities in sleep architecture). Results— There was a significant relationship between obstructive sleep apnea and cardioembolic stroke mechanism compared with the other stroke mechanisms ( P =0.018). There was no significant relationship between obstructive sleep apnea and ESUS ( P =0.585). Patients with ESUS were significantly more likely to have an elevated periodic limb movement index ( P =0.037) and prolonged sleep onset latency ( P =0.0166) compared with patients with other causes of stroke. Conclusions— ESUS was not associated with markers of cardioembolic stroke such as obstructive sleep apnea. There was a significant relationship between ESUS and elevated periodic limb movements and impaired sleep architecture, which suggests that ESUS may have a multifactorial underlying pathophysiology.
- Published
- 2020
233. Slowed Temporal and Parietal Cerebrovascular Response in Patients with Alzheimer's Disease
- Author
-
Julien Poublanc, Adrian P. Crawley, Kenneth R. Holmes, David J. Mikulis, Bruce A. Wasserman, James Duffin, Olivia Sobczyk, Larissa McKetton, Maria Carmela Tartaglia, David F. Tang-Wai, Melanie Cohn, Joseph A. Fisher, Sandra E. Black, and Kevin Sam
- Subjects
Male ,medicine.medical_specialty ,Posterior parietal cortex ,Disease ,Stimulus (physiology) ,Hypercapnia ,symbols.namesake ,Alzheimer Disease ,Internal medicine ,Parietal Lobe ,medicine ,Dementia ,Humans ,Cognitive Dysfunction ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Microangiopathy ,Magnetic resonance imaging ,General Medicine ,Carbon Dioxide ,Middle Aged ,medicine.disease ,Neurovascular bundle ,Magnetic Resonance Imaging ,Temporal Lobe ,Cerebrovascular Disorders ,Bonferroni correction ,Neurology ,Case-Control Studies ,Cerebrovascular Circulation ,symbols ,Cardiology ,Female ,Neurology (clinical) ,business - Abstract
Background:Recent investigations now suggest that cerebrovascular reactivity (CVR) is impaired in Alzheimer’s disease (AD) and may underpin part of the disease’s neurovascular component. However, our understanding of the relationship between the magnitude of CVR, the speed of cerebrovascular response, and the progression of AD is still limited. This is especially true in patients with mild cognitive impairment (MCI), which is recognized as an intermediate stage between normal aging and dementia. The purpose of this study was to investigate AD and MCI patients by mapping repeatable and accurate measures of cerebrovascular function, namely the magnitude and speed of cerebrovascular response (τ) to a vasoactive stimulus in key predilection sites for vascular dysfunction in AD.Methods:Thirty-three subjects (age range: 52–83 years, 20 males) were prospectively recruited. CVR and τ were assessed using blood oxygen level-dependent MRI during a standardized carbon dioxide stimulus. Temporal and parietal cortical regions of interest (ROIs) were generated from anatomical images using the FreeSurfer image analysis suite.Results:Of 33 subjects recruited, 3 individuals were excluded, leaving 30 subjects for analysis, consisting of 6 individuals with early AD, 11 individuals with MCI, and 13 older healthy controls (HCs). τ was found to be significantly higher in the AD group compared to the HC group in both the temporal (p = 0.03) and parietal cortex (p = 0.01) following a one-way ANCOVA correcting for age and microangiopathy scoring and a Bonferroni post-hoc correction.Conclusion:The study findings suggest that AD is associated with a slowing of the cerebrovascular response in the temporal and parietal cortices.
- Published
- 2020
234. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
- Author
-
Jean-Paul Soucy, Serge Gauthier, Dallas Seitz, Cccdtd participants, Isabelle Vedel, Saskia Sivananthan, Kenneth Rockwood, Robert Laforce, Zahinoor Ismail, Howard Chertkow, Manuel Montero-Odasso, Pedro Rosa-Neto, Nathan Herrmann, Sandra E. Black, Eric E. Smith, and Richard Camicioli
- Subjects
medicine.medical_specialty ,Canada ,Epidemiology ,Steering committee ,Psychological intervention ,MEDLINE ,Disease ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Developmental Neuroscience ,mental disorders ,medicine ,Dementia ,Humans ,030212 general & internal medicine ,Cognitive impairment ,business.industry ,Health Policy ,Consensus conference ,medicine.disease ,Psychiatry and Mental health ,Family medicine ,Perspective ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Psychosocial ,030217 neurology & neurosurgery - Abstract
Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence‐based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non‐cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non‐pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence‐based approach to dementia.
- Published
- 2020
235. Abstract 1: Optical Coherence Tomography Imaging in Acute Ischemic Stroke: Preliminary Animal and Human Results
- Author
-
Christopher R. Pasarikovski, Yuta Dobashi, Joel Ramjist, Victor X. D. Yang, Leodante Dacosta, Julia Keith, and Sandra E. Black
- Subjects
Advanced and Specialized Nursing ,medicine.medical_specialty ,genetic structures ,Endothelium ,medicine.diagnostic_test ,business.industry ,medicine.disease ,medicine.anatomical_structure ,Optical coherence tomography ,cardiovascular system ,medicine ,Neurology (clinical) ,Radiology ,Tomography ,Thrombus ,Cardiology and Cardiovascular Medicine ,business ,Acute ischemic stroke - Abstract
Background: Studies evaluating endothelial injury after EVT have been done by means of retrieved human thrombus, MR vessel-wall imaging, and animal histopathologic studies. These techniques have limitations, as MR imaging has insufficient spatial resolution to directly visualize endothelium, and histopathologic examinations are ex-vivo and unable to provide real-time patterns of injury. Objective: Endovascular imaging after EVT using optical coherence tomography (OCT) to examine for vessel injury in real-time. Methodology: Three swine weighing 35-40kg were selected for the animal model. Autologous venous whole-blood was used to create thrombus. A second-generation stent retriever was used for EVT. Next, three consecutive patients with basilar artery occlusion underwent EVT and endovascular OCT imaging. Results: In the animal model, revascularization and OCT imaging was successful for all 9 vessels. Endothelial injury was observed in 4/9 (44%) of vessels, and residual thrombus was observed in 4/9 (44%) of vessels despite complete angiographic revascularization. All vessels undergoing EVT after 6 hours had evidence of endothelial injury, and 2/3 (66%) had residual thrombus. Two basilar stroke patients (2/3) 66% had significant residual thrombus despite complete angiographic revascularization. The residual thrombus was also not visible on CT angiography or MR imaging done within 24 hours of EVT. Conclusions: Endothelial injury and residual thrombus despite complete revascularization is present after EVT and can be observed in real-time using OCT. It is possible that the longer occlusive thrombus is present, the more endothelial injury will occur during EVT.
- Published
- 2020
- Full Text
- View/download PDF
236. An overview of the quality assurance and quality control of magnetic resonance imaging data for the Ontario Neurodegenerative Disease Research Initiative (ONDRI): pipeline development and neuroinformatics
- Author
-
Sean P. Symons, Steven C. Strother, Chemparathy A, Igor Solovey, Joel Ramirez, Gregory M. Szilagyi, Liang S, Sofia Chavez, Mojdeh Zamyadi, Nancy J. Lobaugh, Sandra E. Black, Miracle Ozzoude, Nuwan D. Nanayakkara, Tom Gee, Robert Bartha, Dong F, Schmah T, Melissa F. Holmes, Christopher J.M. Scott, and Arnott
- Subjects
Protocol (science) ,medicine.medical_specialty ,Stroke patient ,business.industry ,Computer science ,Neuroinformatics ,Disease ,medicine.disease ,Neuroimaging ,Informatics ,medicine ,Dementia ,Medical physics ,Amyotrophic lateral sclerosis ,business ,Cognitive impairment ,Quality assurance - Abstract
Large scale research studies combining magnetic resonance imaging data generated at multiple sites on multiple vendor platforms are becoming more commonplace. The Ontario Neurodegenerative Disease Research Initiative (ONDRI - http://ondri.ca/), a project funded by the Ontario Brain Institute (OBI), is a recently established province-wide natural history study, which has recruited more than 500 participants from neurodegenerative disease groups including amyotrophic lateral sclerosis, fronto-temporal dementia, Parkinson’s disease, Alzheimer’s disease, mild cognitive impairment, and cerebrovascular disease (previously referred to as the vascular cognitive impairment cohort). Because of its multi-site nature, all captured data must be standardized and meet minimum quality standards to reduce variability. The goal of the ONDRI imaging platform is to maximize data quality by implementing vendor-specific harmonized MR imaging protocols (consistent with the Canadi-an Dementia Imaging Protocol - http://www.cdip-pcid.ca/), monitoring protocol adherence, qualitatively assessing image quality, measuring signal-to-noise and contrast-to-noise, monitoring system stability, and applying corrections based on the analysis of images from two different phantoms regularly acquired at each site. To maximize image quality, this work describes the use of various automatic pipelines and manual assessment steps, integrated within an established informatics and databasing platform, the Stroke Patient Recovery Research Database (SPReD) built on the Extensible Neuroimaging Archive Toolkit (XNAT), and contained within the Brain-CODE (Centre for Ontario Data Exploration) framework. The purpose of the current paper is to describe the steps undertaken by ONDRI to achieve this high standard of data integrity. Data have been successfully collected for the past 4 years with the pipelines and assessments identifying deviations, allowing for timely interventions and assessment of image quality.
- Published
- 2020
- Full Text
- View/download PDF
237. Perivascular spaces in the brain:anatomy, physiology and pathology
- Author
-
Joel Ramirez, Hedok Lee, Davide Boido, Joanna M. Wardlaw, Ravi L. Rungta, Humberto Mestre, Fergus N. Doubal, Kenneth Smith, Rosalind Brown, Bradley J. MacIntosh, Anne Joutel, Helene Benveniste, Lucia Ballerini, Allen Tannenbaum, Serge Charpak, Axel Montagne, Berislav V. Zlokovic, Sandra E. Black, and Melanie D. Sweeney
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Brain Diseases/diagnostic imaging ,Physiology ,Vascular risk ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Brain anatomy ,0302 clinical medicine ,Neuroimaging ,medicine ,Animals ,Humans ,Perivascular space ,Brain Diseases ,business.industry ,medicine.disease ,Sleep patterns ,030104 developmental biology ,medicine.anatomical_structure ,Brain lesions ,Glymphatic System/anatomy & histology ,Wakefulness ,Neurology (clinical) ,Alzheimer's disease ,business ,Glymphatic System ,030217 neurology & neurosurgery - Abstract
Perivascular spaces include a variety of passageways around arterioles, capillaries and venules in the brain, along which a range of substances can move. Although perivascular spaces were first identified over 150 years ago, they have come to prominence recently owing to advances in knowledge of their roles in clearance of interstitial fluid and waste from the brain, particularly during sleep, and in the pathogenesis of small vessel disease, Alzheimer disease and other neurodegenerative and inflammatory disorders. Experimental advances have facilitated in vivo studies of perivascular space function in intact rodent models during wakefulness and sleep, and MRI in humans has enabled perivascular space morphology to be related to cognitive function, vascular risk factors, vascular and neurodegenerative brain lesions, sleep patterns and cerebral haemodynamics. Many questions about perivascular spaces remain, but what is now clear is that normal perivascular space function is important for maintaining brain health. Here, we review perivascular space anatomy, physiology and pathology, particularly as seen with MRI in humans, and consider translation from models to humans to highlight knowns, unknowns, controversies and clinical relevance.
- Published
- 2020
- Full Text
- View/download PDF
238. Winners and Losers? The Effect of Gaining and Losing Access to Selective Colleges on Education and Labor Market Outcomes
- Author
-
Sandra E. Black, Jeffrey T. Denning
- Published
- 2020
- Full Text
- View/download PDF
239. Lactate topography of the human brain using hyperpolarized 13C-MRI
- Author
-
Charles H. Cunningham, Casey Y. Lee, William J. Perks, Benjamin J. Geraghty, Chris Heyn, Kim A. Connelly, Ruby Endre, Sandra E. Black, Hany Soliman, and Albert P. Chen
- Subjects
Cognitive Neuroscience ,Bicarbonate ,Precuneus ,ANLS ,050105 experimental psychology ,Cuneus ,lcsh:RC321-571 ,White matter ,Lingual gyrus ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Nuclear magnetic resonance ,medicine ,0501 psychology and cognitive sciences ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Chemistry ,05 social sciences ,Brain atlas ,Human brain ,medicine.anatomical_structure ,Metabolism ,Neurology ,Anaerobic glycolysis ,Lactate ,Aerobic glycolysis ,Hyperpolarized 13C MRI ,030217 neurology & neurosurgery - Abstract
Lactate is now recognized as an important intermediate in brain metabolism, but its role is still under investigation. In this work we mapped the distribution of lactate and bicarbonate produced from intravenously injected 13C-pyruvate over the whole brain using a new imaging method, hyperpolarized 13C MRI (N = 14, ages 23 to 77). Segmenting the 13C-lactate images into brain atlas regions revealed a pattern of lactate that was preserved across individuals. Higher lactate signal was observed in cortical grey matter compared to white matter and was highest in the precuneus, cuneus and lingual gyrus. Bicarbonate signal, indicating flux of [1–13C]pyruvate into the TCA cycle, also displayed consistent spatial distribution. One-way ANOVA to test for significant differences in lactate among atlas regions gave F = 87.6 and p
- Published
- 2020
240. Pathophysiology of Vascular Cognitive Impairment (I): Theoretical Background
- Author
-
Di Yu, Walter Swardfager, and Sandra E. Black
- Subjects
Pathogenesis ,Cerebral circulation ,business.industry ,medicine ,Dementia ,Cognition ,Disease ,medicine.disease ,business ,Stroke ,Pathological ,Neuroscience ,Homeostasis - Abstract
Vascular cognitive impairment (VCI) describes a spectrum of cognitive changes occurring secondary to damage of the large and small vessels that supply blood to the brain. VCI has been recognized as the second most common cause of dementia and as the most common pathological comorbidity of Alzheimer’s disease. The pathogenesis of VCI appears to be heterogeneous, involving neurodegenerative mechanisms that remain to be fully understood. Stroke and vascular risk factors interfere with many processes subserved by the cerebral vasculature, maintaining cerebral homeostasis (for instance, maintaining and augmenting blood flow, oxygen, glucose supply), providing a structural and chemical barrier between the peripheral circulation and the brain parenchyma, serving intricate immunological functions, and providing a neurogenic niche for brain tissue repair. This chapter discusses the known and theoretical pathophysiological background of VCI, focusing on stroke and disruption of the neurovascular unit (NVU), which contribute to defects in neurotransmitter systems and to disruption of large-scale functionally co-activating networks, which contributes to cognitive deficits and decline.
- Published
- 2020
- Full Text
- View/download PDF
241. Soluble Epoxide Hydrolase-Derived Linoleic Acid Oxylipins in Serum Are Associated with Periventricular White Matter Hyperintensities and Vascular Cognitive Impairment
- Author
-
Pak Cheung Chan, Demetrios J. Sahlas, Joel Ramirez, Mario Masellis, Donald T. Stuss, Jacqueline A. Pettersen, Fuqiang Gao, Ameer Y. Taha, Nathan Herrmann, Di Yu, Sandra E. Black, Walter Swardfager, Hugo Cogo-Moreira, Marie Hennebelle, and Richard H. Swartz
- Subjects
Male ,0301 basic medicine ,Epoxide hydrolase 2 ,medicine.medical_specialty ,Neurology ,Metabolite ,Linoleic acid ,Cerebral Ventricles ,Linoleic Acid ,White matter ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,Cognitive Dysfunction ,Oxylipins ,Vascular Diseases ,Aged ,Epoxide Hydrolases ,chemistry.chemical_classification ,business.industry ,Vascular disease ,General Neuroscience ,medicine.disease ,White Matter ,Hyperintensity ,Cross-Sectional Studies ,030104 developmental biology ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Female ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers ,030217 neurology & neurosurgery ,Polyunsaturated fatty acid - Abstract
White matter hyperintensities (WMH) are presumed to indicate subcortical ischemic vascular disease but their underlying pathobiology remains incompletely understood. The soluble epoxide hydrolase (sEH) enzyme converts anti-inflammatory and vasoactive cytochrome p450-derived polyunsaturated fatty acid epoxides into their less active corresponding diol species. Under the hypothesis that the activity of sEH might be associated with subcortical ischemic vascular disease and vascular cognitive impairment, this study aimed to compare the relative abundance of sEH substrates and products in peripheral blood between patients with extensive WMH (discovered due to transient ischemic attack; n = 29) and healthy elderly with minimal WMH (n = 25). The concentration of 12,13-DiHOME (a sEH-derived linoleic acid metabolite), and the ratio of 12,13-DiHOME to its sEH substrate, 12,13-EpOME, were elevated in the extensive WMH group (F1,53 = 5.9, p = 0.019), as was the 9,10-DiHOME/9,10-EpOME ratio (F1,53 = 5.4, p = 0.024). The 12,13-DiHOME/12,13-EpOME ratio was associated with poorer performance on a composite score derived from tests of psychomotor processing speed, attention, and executive function (β = - 0.473, p = 0.001, adjusted r2 = 0.213), but not with a composite verbal memory score. In a mediation model, periventricular WMH (but not deep WMH), explained 37% of the effect of the 12,13-DiHOME/12,13-EpOME ratio on the speed/attention/executive function composite score (indirect effect = - 0.50, 95% bootstrap confidence interval [- 0.99, - 0.17] Z-score units). Serum oxylipin changes consistent with higher sEH activity were markers of vascular cognitive impairment, and this association was partly explained by injury to the periventricular subcortical white matter.
- Published
- 2018
- Full Text
- View/download PDF
242. Therapeutic trial design for frontotemporal dementia and related disorders
- Author
-
Bradford C. Dickerson, Howard Feldman, Nathan Herrmann, Donald T. Stuss, Adam L. Boxer, Quoc Dinh Nguyen, Howie Rosen, Maria Carmela Tartaglia, Mario Masellis, Lieke H.H. Meeter, Jonathan D. Rohrer, John C. van Swieten, Philippe Desmarais, Barbara Borroni, Anthony E. Lang, Sandra E. Black, and Neurology
- Subjects
Outcome Assessment ,Neurodegenerative ,frontotemporal dementia ,Medical and Health Sciences ,0302 clinical medicine ,Outcome Assessment, Health Care ,Supranuclear Palsy ,Medical diagnosis ,Randomized Controlled Trials as Topic ,randomised trials ,Reference Standards ,Frontotemporal Dementia (FTD) ,Psychiatry and Mental health ,Systematic review ,neurogenetics ,pharmacology ,systematic reviews ,Research Design ,Frontotemporal Dementia ,Neurological ,Supranuclear Palsy, Progressive ,Construct (philosophy) ,Frontotemporal dementia ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Neurogenetics ,Progressive supranuclear palsy ,03 medical and health sciences ,Rare Diseases ,Progressive ,Clinical Research ,Acquired Cognitive Impairment ,medicine ,Humans ,Intensive care medicine ,Neurology & Neurosurgery ,business.industry ,Clinical study design ,Psychology and Cognitive Sciences ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,medicine.disease ,Brain Disorders ,Health Care ,Clinical trial ,Good Health and Well Being ,Dementia ,Surgery ,Neurology (clinical) ,Frontotemporal Lobar Degeneration ,business ,030217 neurology & neurosurgery - Abstract
The frontotemporal dementia (FTD) spectrum is a heterogeneous group of neurodegenerative syndromes with overlapping clinical, molecular and pathological features, all of which challenge the design of clinical trials in these conditions. To date, no pharmacological interventions have been proven effective in significantly modifying the course of these disorders. This study critically reviews the construct and methodology of previously published randomised controlled trials (RCTs) in FTD spectrum disorders in order to identify limitations and potential reasons for negative results. Moreover, recommendations based on the identified gaps are elaborated in order to guide future clinical trial design. A systematic literature review was carried out and presented in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. A total of 23 RCTs in cohorts with diagnoses of behavioural and language variants of FTD, corticobasal syndrome and progressive supranuclear palsy syndrome were identified out of the 943 citations retrieved and were included in the qualitative review. Most studies identified were early-phase clinical trials that were small in size, short in duration and frequently underpowered. Diagnoses of populations enrolled in clinical trials were based on clinical presentation and rarely included precision-medicine tools, such as genetic and molecular testing. Uniformity and standardisation of research outcomes in the FTD spectrum are essential. Several elements should be carefully considered and planned in future clinical trials. We anticipate that precision-medicine approaches will be crucial to adequately address heterogeneity in the FTD spectrum research.
- Published
- 2018
- Full Text
- View/download PDF
243. The Canadian Dementia Imaging Protocol: Harmonizing National Cohorts
- Author
-
Christopher J.M. Scott, Vladimir S. Fonov, Cheryl R. McCreary, Joel Ramirez, Pierre Bellec, Maxime Descoteaux, Simon Duchesne, April Khademi, Isabelle Chouinard, Sandra E. Black, Richard D. Hoge, D. Louis Collins, Robert Bartha, Eric E. Smith, Olivier Potvin, and Stephen C. Strother
- Subjects
Quality Control ,Aging ,Canada ,Quality Assurance, Health Care ,Siemens ,Signal-To-Noise Ratio ,resting state functional MRI ,Imaging phantom ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Neuroimaging ,Alzheimer Disease ,Humans ,magnetic resonance imaging ,Medicine ,Dementia ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,standardization ,neuroimaging ,Resting state fMRI ,medicine.diagnostic_test ,Phantoms, Imaging ,business.industry ,Brain ,Reproducibility of Results ,Neurodegenerative Diseases ,Magnetic resonance imaging ,diffusion tensor imaging ,medicine.disease ,Magnetic Resonance Imaging ,3. Good health ,Linear Models ,Medical Biophysics ,business ,Nuclear medicine ,Quality assurance ,Algorithms ,morphometry ,Diffusion MRI - Abstract
© 2018 International Society for Magnetic Resonance in Medicine Background: Harmonized protocols to collect imaging data must be devised, employed, and maintained in multicentric studies to reduce interscanner variability in subsequent analyses. Purpose: To present a standardized protocol for multicentric research on dementia linked to neurodegeneration in aging, harmonized on all three major vendor platforms. The protocol includes a common procedure for qualification, quality control, and quality assurance and feasibility in large-scale studies. Study Type: Prospective. Subjects: The study involved a geometric phantom, a single individual volunteer, and 143 cognitively healthy, mild cognitively impaired, and Alzheimer's disease participants in a large-scale, multicentric study. Field Strength/Sequences: MRI was perform with 3T scanners (GE, Philips, Siemens) and included 3D T 1 w, PD/T 2 w, T *2 , T 2 w-FLAIR, diffusion, and BOLD resting state acquisitions. Assessment: Measures included signal- and contrast-to-noise ratios (SNR and CNR, respectively), total brain volumes, and total scan time. Statistical Tests: SNR, CNR, and scan time were compared between scanner vendors using analysis of variance (ANOVA) and Tukey tests, while brain volumes were tested using linear mixed models. Results: Geometric phantom T 1 w SNR was significantly (P < 0.001) higher in Philips (mean: 71.4) than Siemens (29.5), while no significant difference was observed between vendors for T 2 w (32.0 and 37.2, respectively, P = 0.243). Single individual volunteer T 1 w CNR was higher in subcortical regions for Siemens (P < 0.001), while Philips had higher cortical CNR (P = 0.044). No significant difference in brain volumes was observed between vendors (P = 0.310/0.582/0.055). The average scan time was 41.0 minutes (SD: 2.8) and was not significantly different between sites (P = 0.071) and cognitive groups (P = 0.853). Data Conclusion: The harmonized Canadian Dementia Imaging Protocol suits the needs of studies that need to ensure quality MRI data acquisition for the measurement of brain changes across adulthood, due to aging, neurodegeneration, and other etiologies. A detailed description, exam cards, and operators' manual are freely available at the following site: www.cdip-pcid.ca. Level of Evidence: 2. Technical Efficacy: Stage 2. J. Magn. Reson. Imaging 2019;49:456–465.
- Published
- 2018
- Full Text
- View/download PDF
244. Clinical dementia severity associated with ventricular size is differentially moderated by cognitive reserve in men and women
- Author
-
Donald T. Stuss, Joel Ramirez, Shraddha Sapkota, Sandra E. Black, and Mario Masellis
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neurology ,Cognitive Neuroscience ,Intelligence ,Cognitive reserve ,Disease ,Severity of Illness Index ,Ventricular size ,050105 experimental psychology ,lcsh:RC346-429 ,Cerebral Ventricles ,lcsh:RC321-571 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Dementia ,Humans ,0501 psychology and cognitive sciences ,Occupations ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Aged, 80 and over ,Intelligence Tests ,business.industry ,Latent growth modeling ,Research ,05 social sciences ,Sunnybrook Dementia Study ,Middle Aged ,medicine.disease ,Confirmatory factor analysis ,3. Good health ,Cognitive impairment ,Disease Progression ,Female ,Sex ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Geriatric psychiatry ,Frontotemporal dementia - Abstract
Background Interindividual differences in cognitive reserve (CR) are associated with complex and dynamic clinical phenotypes observed in cognitive impairment and dementia. We tested whether (1) CR early in life (E-CR; measured by education and IQ), (2) CR later in life (L-CR; measured by occupation), and (3) CR panel (CR-P) with the additive effects of E-CR and L-CR, act as moderating factors between baseline ventricular size and clinical dementia severity at baseline and across 2 years. We further examined whether this moderation is differentially represented by sex. Methods We examined a longitudinal model using patients (N = 723; mean age = 70.8 ± 9.4 years; age range = 38–90 years; females = 374) from the Sunnybrook Dementia Study. The patients represented Alzheimer’s disease (n = 439), mild cognitive impairment (n = 77), vascular cognitive impairment (n = 52), Lewy body disease (n = 30), and frontotemporal dementia (n = 125). Statistical analyses included (1) latent growth modeling to determine how clinical dementia severity changes over 2 years (measured by performance on the Dementia Rating Scale), (2) confirmatory factor analysis to establish a baseline E-CR factor, and (3) path analysis to predict dementia severity. Baseline age (continuous) and Apolipoprotein E status (ɛ4−/ɛ4+) were included as covariates. Results The association between higher baseline ventricular size and dementia severity was moderated by (1) E-CR and L-CR and (2) CR-P. This association was differentially represented in men and women. Specifically, men in only the low CR-P had higher baseline clinical dementia severity with larger baseline ventricular size. However, women in the low CR-P showed the (1) highest baseline dementia severity and (2) fastest 2-year decline with larger baseline ventricular size. Conclusions Clinical dementia severity associated with ventricular size may be (1) selectively moderated by complex and additive CR networks and (2) differentially represented by sex. Trials registration ClinicalTrials.gov, NCT01800214. Registered on 27 February 2013. Electronic supplementary material The online version of this article (10.1186/s13195-018-0419-2) contains supplementary material, which is available to authorized users.
- Published
- 2018
- Full Text
- View/download PDF
245. A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease
- Author
-
Di Yu, Walter Swardfager, Michael Ouk, Saffire H. Krance, Che-Yuan Wu, Hugo Cogo-Moreira, Sandra E. Black, Kritleen K. Bawa, Krista L. Lanctôt, and Nathan Herrmann
- Subjects
Oncology ,Male ,Neurology ,Neutrophils ,lcsh:RC346-429 ,Executive Function ,Chemokine CCL4 ,Neutrophil gelatinase-associated Lipocalin ,Aged, 80 and over ,Myeloperoxidase ,Macrophage inflammatory protein-1 beta ,biology ,medicine.diagnostic_test ,General Neuroscience ,Neutrophil ,Middle Aged ,Disease Progression ,Tumor necrosis factor alpha ,Female ,medicine.symptom ,Alzheimer’s disease ,medicine.medical_specialty ,Tumor necrosis factor ,Immunology ,Inflammation ,Cellular and Molecular Neuroscience ,Atrophy ,Lipocalin-2 ,Alzheimer Disease ,Memory ,Internal medicine ,medicine ,Humans ,Effects of sleep deprivation on cognitive performance ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Peroxidase ,Mini–Mental State Examination ,business.industry ,Tumor Necrosis Factor-alpha ,Research ,Interleukin-8 ,medicine.disease ,Hyperintensity ,biology.protein ,business ,Biomarkers - Abstract
Background Studies suggest a role of the innate immune system, including the activity of neutrophils, in neurodegeneration related to Alzheimer’s disease (AD), but prospective cognitive data remain lacking in humans. We aimed to investigate the predictive relationship between neutrophil-associated inflammatory proteins in peripheral blood and changes in memory and executive function over 1 year in patients with AD. Methods Participants with AD were identified from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neutrophil gelatinase-associated lipocalin (NGAL), myeloperoxidase (MPO), interleukin-8 (IL-8), macrophage inflammatory protein-1 beta (MIP-1β), and tumor necrosis factor (TNF) were assayed by luminex immunofluorescence multiplex assay at baseline. Confirmatory factor analysis was used to test an underlying neutrophil associated plasma inflammatory factor. Composite z-scores for memory and executive function were generated from multiple tests at baseline and at 1 year. A multiple linear regression model was used to investigate the association of the baseline inflammatory factor with changes in memory and executive function over 1 year. Results Among AD patients (n = 109, age = 74.8 ± 8.1, 42% women, Mini Mental State Examination [MMSE] = 23.6 ± 1.9), the neutrophil-related inflammatory proteins NGAL (λ = 0.595, p λ = 0.575, p λ = 0.525, p λ = 0.411, p = .008), and TNF (λ = 0.475, p β = − 0.152, p = 0.015) but not memory (β = 0.030, p = 0.577) in models controlling for demographics, brain atrophy, white matter hyperintensities, the ApoE ε4 allele, concomitant medications, and baseline cognitive performance. Conclusions An inflammatory factor constructed from five neutrophil-related markers in peripheral blood predicted a decline in executive function over 1 year in people with mild AD.
- Published
- 2019
246. Ontario Neurodegenerative Disease Research Initiative (ONDRI): Structural MRI methods & outcome measures
- Author
-
Fuqiang Gao, Stephen R. Arnott, Miracle Ozzoude, Gregory M. Szilagyi, Sandra E. Black, Christopher J.M. Scott, Jane M. Lawrence-Dewar, Sean P. Symons, Richard H. Swartz, Sabrina Adamo, Mario Masellis, Derek Beaton, Maged Goubran, Douglas P. Munoz, Stephen C. Strother, Joel Ramirez, Melissa F. Holmes, and Robert Bartha
- Subjects
medicine.medical_specialty ,business.industry ,Disease ,medicine.disease ,Neurovascular bundle ,Research initiative ,Physical medicine and rehabilitation ,Neuroimaging ,medicine ,Amyotrophic lateral sclerosis ,Prospective cohort study ,business ,Pathological ,Frontotemporal dementia - Abstract
The Ontario Neurodegenerative Research Initiative (ONDRI) is a 3 year multi-site prospective cohort study that has acquired comprehensive multiple assessment platform data, including 3T structural MRI, from neurodegenerative patients with Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and cerebrovascular disease patients. This heterogeneous cross-section of patients with complex neurodegenerative and neurovascular pathologies pose significant challenges for standard neuroimaging tools. To effectively quantify regional measures of normal and pathological brain tissue volumes, the ONDRI neuroimaging platform implemented a semi-automated MRI processing pipeline that was able to address many of the challenges resulting from this heterogeneity. This paper describes the comprehensive neuroimaging pipeline methods used to generate regional brain tissue volumes & neurovascular markers.
- Published
- 2019
- Full Text
- View/download PDF
247. Comparison of quality control methods for automated diffusion tensor imaging analysis pipelines
- Author
-
Seyyed M. H. Haddad, Christopher J.M. Scott, Stephen R. Arnott, Melissa F. Holmes, Dar Dowlatshahi, Richard H. Swartz, Sandra E. Black, Ondri Investigators, Robert Bartha, Manuel Montero-Odasso, Miracle Ozzoude, Joel Ramirez, Nuwan D. Nanayakkara, Sean P. Symons, and Stephen C. Strother
- Subjects
Male ,Computer science ,Image Processing ,Diagnostic Radiology ,030218 nuclear medicine & medical imaging ,Cohort Studies ,0302 clinical medicine ,Medicine and Health Sciences ,Longitudinal Studies ,Gray Matter ,Aged, 80 and over ,Ontario ,Brain Mapping ,Ground truth ,Data Processing ,Multidisciplinary ,medicine.diagnostic_test ,Radiology and Imaging ,Middle Aged ,White Matter ,Magnetic Resonance Imaging ,Diffusion Tensor Imaging ,Data Acquisition ,medicine.anatomical_structure ,Medicine ,Engineering and Technology ,Female ,Artifacts ,Information Technology ,Algorithms ,Research Article ,Quality Control ,Computer and Information Sciences ,Imaging Techniques ,Science ,Brain Morphometry ,Graphics Pipelines ,Neuroimaging ,Image processing ,Grey matter ,Research and Analysis Methods ,White matter ,03 medical and health sciences ,Diagnostic Medicine ,Computational Techniques ,Fractional anisotropy ,medicine ,Humans ,Cognitive Dysfunction ,Aged ,Electronic Data Processing ,Artifact (error) ,Diffusion Weighted Imaging ,business.industry ,Computational Pipelines ,Biology and Life Sciences ,Magnetic resonance imaging ,Pattern recognition ,Pipeline (software) ,Signal Processing ,Medical Biophysics ,Anisotropy ,Artificial intelligence ,business ,Software ,030217 neurology & neurosurgery ,Neuroscience ,Diffusion MRI - Abstract
© 2019 Haddad et al. The processing of brain diffusion tensor imaging (DTI) data for large cohort studies requires fully automatic pipelines to perform quality control (QC) and artifact/outlier removal procedures on the raw DTI data prior to calculation of diffusion parameters. In this study, three automatic DTI processing pipelines, each complying with the general ENIGMA framework, were designed by uniquely combining multiple image processing software tools. Different QC procedures based on the RESTORE algorithm, the DTIPrep protocol, and a combination of both methods were compared using simulated ground truth and artifact containing DTI datasets modeling eddy current induced distortions, various levels of motion artifacts, and thermal noise. Variability was also examined in 20 DTI datasets acquired in subjects with vascular cognitive impairment (VCI) from the multi-site Ontario Neurodegenerative Disease Research Initiative (ONDRI). The mean fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated in global brain grey matter (GM) and white matter (WM) regions. For the simulated DTI datasets, the measure used to evaluate the performance of the pipelines was the normalized difference between the mean DTI metrics measured in GM and WM regions and the corresponding ground truth DTI value. The performance of the proposed pipelines was very similar, particularly in FA measurements. However, the pipeline based on the RESTORE algorithm was the most accurate when analyzing the artifact containing DTI datasets. The pipeline that combined the DTIPrep protocol and the RESTORE algorithm produced the lowest standard deviation in FA measurements in normal appearing WM across subjects. We concluded that this pipeline was the most robust and is preferred for automated analysis of multisite brain DTI data.
- Published
- 2019
248. PET/CT of Dementia
- Author
-
Rathan M. Subramaniam, Phillip H. Kuo, David J. Mikulis, Antonio P. Strafella, Pedro Rosa-Neto, Katherine Zukotynski, and Sandra E. Black
- Subjects
PET-CT ,medicine.medical_specialty ,business.industry ,General Medicine ,medicine.disease ,030218 nuclear medicine & medical imaging ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,Dementia ,Radiology, Nuclear Medicine and imaging ,Radiology ,Radiopharmaceuticals ,business ,030217 neurology & neurosurgery - Abstract
In this article, we review the literature on PET/CT in the management of dementia, present evidence for best clinical practices, and discuss recent advances in the field.Standard-of-care imaging for dementia includes CT and MRI, primarily for excluding vascular lesions or masses, detecting atrophy, and monitoring disease severity. PET/CT is a powerful functional modality that can differentiate dementia types and influence management. Fluorine-18-FDG PET/CT reveals the spatial pattern of glucose metabolism in the brain. More recently, radiotracers for PET have been developed that bind to amyloid protein, tau protein, and neuroinflammatory markers.
- Published
- 2018
- Full Text
- View/download PDF
249. The Toronto Cognitive Assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment
- Author
-
Barry D. Greenberg, Larry Leach, Josh Kirstein, Mary Pat McAndrews, Nicolaas Paul L.G. Verhoeff, David F. Tang-Wai, Nima Nourhaghighi, Corinne E. Fischer, M. Uri Wolf, Tom Gee, Michelle Gyenes, Sandra E. Black, M. Carmela Tartaglia, Kathryn A. Stokes, Stephen C. Strother, Gary Naglie, Mohammad Alhaj, Jennifer Fogarty, William Reichmann, Suvendrini Lena, Ron Keren, Sanjeev Kumar, Benjamin Lam, Jordana L. Waserman, Robert Partridge, Robyn Spring, Yael Goldberg, Alita Fernandez, Sultan Darvesh, Nathan Herrmann, Tarek K. Rajji, Michael Borrie, and Morris Freedman
- Subjects
Male ,medicine.medical_specialty ,Neurology ,Cognitive Neuroscience ,Neuropsychological Tests ,Logistic regression ,lcsh:RC346-429 ,lcsh:RC321-571 ,Normative study ,03 medical and health sciences ,0302 clinical medicine ,Cognitive assessment ,Reference Values ,Diagnosis ,Validation ,medicine ,Humans ,Cognitive Dysfunction ,Neuropsychological assessment ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,lcsh:Neurology. Diseases of the nervous system ,Aged ,Aged, 80 and over ,030214 geriatrics ,medicine.diagnostic_test ,Recall ,Working memory ,Research ,Age Factors ,Reproducibility of Results ,Correction ,Mild cognitive impairment ,Cognition ,Middle Aged ,TorCA ,Normative ,Female ,Amnesia ,Neurology (clinical) ,Psychology ,Toronto Cognitive Assessment ,030217 neurology & neurosurgery ,Geriatric psychiatry ,Clinical psychology - Abstract
Background A need exists for easily administered assessment tools to detect mild cognitive changes that are more comprehensive than screening tests but shorter than a neuropsychological battery and that can be administered by physicians, as well as any health care professional or trained assistant in any medical setting. The Toronto Cognitive Assessment (TorCA) was developed to achieve these goals. Methods We obtained normative data on the TorCA (n = 303), determined test reliability, developed an iPad version, and validated the TorCA against neuropsychological assessment for detecting amnestic mild cognitive impairment (aMCI) (n = 50/57, aMCI/normal cognition). For the normative study, healthy volunteers were recruited from the Rotman Research Institute registry. For the validation study, the sample was comprised of participants with aMCI or normal cognition based on neuropsychological assessment. Cognitively normal participants were recruited from both healthy volunteers in the normative study sample and the community. Results The TorCA provides a stable assessment of multiple cognitive domains. The total score correctly classified 79% of participants (sensitivity 80%; specificity 79%). In an exploratory logistic regression analysis, indices of Immediate Verbal Recall, Delayed Verbal and Visual Recall, Visuospatial Function, and Working Memory/Attention/Executive Control, a subset of the domains assessed by the TorCA, correctly classified 92% of participants (sensitivity 92%; specificity 91%). Paper and iPad version scores were equivalent. Conclusions The TorCA can improve resource utilization by identifying patients with aMCI who may not require more resource-intensive neuropsychological assessment. Future studies will focus on cross-validating the TorCA for aMCI, and validation for disorders other than aMCI.
- Published
- 2018
- Full Text
- View/download PDF
250. Sleep on the ward in intensive care unit survivors: a case series of polysomnography
- Author
-
Mary Elizabeth Wilcox, Andrew S P Lim, Ruxandra Pinto, Mary Pat McAndrews, Gordon D. Rubenfeld, and Sandra E. Black
- Subjects
medicine.medical_specialty ,Sleep hygiene ,Hypnogram ,medicine.diagnostic_test ,business.industry ,Psychological intervention ,030208 emergency & critical care medicine ,Polysomnography ,Intensive care unit ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Interquartile range ,law ,Intensive care ,Emergency medicine ,Internal Medicine ,Medicine ,Sleep (system call) ,business - Abstract
Background Few studies have investigated sleep in patients after intensive care despite the possibility that inadequate sleep might further complicate an acute illness impeding recovery. Aims To assess the quality and quantity of a patient's sleep on the ward by polysomnography (PSG) within a week of intensive care unit (ICU) discharge and to explore the prevalence of key in-ICU risk factors for persistent sleep fragmentation. Methods We enrolled 20 patients after they have been mechanically ventilated for at least 3 days and survived to ICU discharge. We included all patients over the age of 16 years and excluded patients with advanced cognitive impairment or who were unable to follow simple commands before their acute illness, primary admission diagnosis of neurological injury, uncontrolled psychiatric illness or not fluent in English. Results Twenty patients underwent an overnight PSG recording on day 7 after ICU discharge (SD, 1 day). ICU survivors provided 292.8 h of PSG recording time with median recording times of 16.8 h (Interquartile range (IQR), 15.0-17.2 h). The median total sleep time per patient was 5.3 h (IQR, 2.6-6.3 h). In a multivariable regression model, postoperative admission diagnosis (P = 0.04) and patient report of poor ICU sleep (P = 0.001) were associated with less slow-wave (restorative) sleep on the wards after ICU discharge. Conclusions Patients reported poor sleep while in the ICU, and a postoperative admission diagnosis may identify a high-risk subgroup of patients who may derive greater benefit from interventions to improve sleep hygiene.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.